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ABSTRACT 
MEMS for Diabetic Retinopathy 
 
Thesis by 
Dongyang Kang 
Doctor of Philosophy in Electrical Engineering 
California Institute of Technology 
 
As the worldwide prevalence of diabetes mellitus continues to increase, diabetic 
retinopathy remains the leading cause of visual impairment and blindness in many 
developed countries.  Between 32 to 40 percent of about 246 million people with diabetes 
develop diabetic retinopathy.  Approximately 4.1 million American adults 40 years and 
older are affected by diabetic retinopathy.  This glucose-induced microvascular disease 
progressively damages the tiny blood vessels that nourish the retina, the light-sensitive 
tissue at the back of the eye, leading to retinal ischemia (i.e., inadequate blood flow), 
retinal hypoxia (i.e., oxygen deprivation), and retinal nerve cell degeneration or death.  It 
is a most serious sight-threatening complication of diabetes, resulting in significant 
irreversible vision loss, and even total blindness. 
Unfortunately, although current treatments of diabetic retinopathy (i.e., laser 
therapy, vitrectomy surgery and anti-VEGF therapy) can reduce vision loss, they only 
slow down but cannot stop the degradation of the retina.  Patients require repeated 
treatment to protect their sight.  The current treatments also have significant drawbacks.  
Laser therapy is focused on preserving the macula, the area of the retina that is 
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responsible for sharp, clear, central vision, by sacrificing the peripheral retina since there 
is only limited oxygen supply.  Therefore, laser therapy results in a constricted peripheral 
visual field, reduced color vision, delayed dark adaptation, and weakened night vision.  
Vitrectomy surgery increases the risk of neovascular glaucoma, another devastating 
ocular disease, characterized by the proliferation of fibrovascular tissue in the anterior 
chamber angle.  Anti-VEGF agents have potential adverse effects, and currently there is 
insufficient evidence to recommend their routine use. 
In this work, for the first time, a paradigm shift in the treatment of diabetic 
retinopathy is proposed: providing localized, supplemental oxygen to the ischemic tissue 
via an implantable MEMS device.  The retinal architecture (e.g., thickness, cell densities, 
layered structure, etc.) of the rabbit eye exposed to ischemic hypoxic injuries was well 
preserved after targeted oxygen delivery to the hypoxic tissue, showing that the use of an 
external source of oxygen could improve the retinal oxygenation and prevent the 
progression of the ischemic cascade.   
The proposed MEMS device transports oxygen from an oxygen-rich space to the 
oxygen-deficient vitreous, the gel-like fluid that fills the inside of the eye, and then to the 
ischemic retina.  This oxygen transport process is purely passive and completely driven 
by the gradient of oxygen partial pressure (݌ܱଶ).  Two types of devices were designed.  
For the first type, the oxygen-rich space is underneath the conjunctiva, a membrane 
covering the sclera (white part of the eye), beneath the eyelids and highly permeable to 
oxygen in the atmosphere when the eye is open.  Therefore, sub-conjunctival ݌ܱଶ is very 
high during the daytime.  For the second type, the oxygen-rich space is inside the device 
since pure oxygen is needle-injected into the device on a regular basis. 
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To prevent too fast or too slow permeation of oxygen through the device that is 
made of parylene and silicone (two widely used biocompatible polymers in medical 
devices), the material properties of the hybrid parylene/silicone were investigated, 
including mechanical behaviors, permeation rates, and adhesive forces.  Then the 
thicknesses of parylene and silicone became important design parameters that were fine-
tuned to reach the optimal oxygen permeation rate. 
The passive MEMS oxygen transporter devices were designed, built, and tested in 
both bench-top artificial eye models and in-vitro porcine cadaver eyes.  The 3D unsteady 
saccade-induced laminar flow of water inside the eye model was modeled by 
computational fluid dynamics to study the convective transport of oxygen inside the eye 
induced by saccade (rapid eye movement).  The saccade-enhanced transport effect was 
also demonstrated experimentally.  Acute in-vivo animal experiments were performed in 
rabbits and dogs to verify the surgical procedure and the device functionality.  Various 
hypotheses were confirmed both experimentally and computationally, suggesting that 
both the two types of devices are very promising to cure diabetic retinopathy.  The 
chronic implantation of devices in ischemic dog eyes is still underway. 
The proposed MEMS oxygen transporter devices can be also applied to treat other 
ocular and systemic diseases accompanied by retinal ischemia, such as central retinal 
artery occlusion, carotid artery disease, and some form of glaucoma.   
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction to Blindness and Diabetic Retinopathy 
The leading causes of chronic blindness include cataract, glaucoma, age-related 
macular degeneration, corneal opacities, diabetic retinopathy, trachoma, and eye 
conditions in children (e.g., caused by vitamin A deficiency) [1].  Age-related blindness 
is increasing throughout the world, as is blindness due to uncontrolled diabetes.   
The estimated number of people visually impaired in the world is 285 million, 
with 39 million blind and 246 million having low vision; 65% of people visually 
impaired and 82% of all blind are aged 50 and above (Table 1-1) [2].   
Table 1-1: Global estimate of the number of people visually impaired by age, 2010; for 
all ages in parenthesis the corresponding prevalence (%) [2]. 
Age (in years) Population (millions) 
Blind 
(millions) 
Low Vision 
(millions) 
Visually Impaired 
(millions) 
0 – 14 1848.50 1.421 17.518 18.939 
15 – 49 3548.2 5.784 74.463 80.248 
50 and older 1340.80 32.16 154.043 186.203 
all ages 6737.50 39.365 (0.58) 246.024 (3.65) 285.389 (4.24) 
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The distribution of people visually impaired in the six WHO Regions is shown in 
Table 1-2 with the percentage of the global impairment shown in parentheses [2].  About 
90% of the world's visually impaired live in low-income settings [3]. 
Table 1-2: Number of people visually impaired and corresponding percentage of the 
global impairment by WHO Region and country, 2010 [2]. 
  Blind Low Vision Visually Impaired
WHO Region Total population (millions) 
No. in millions 
(percentage) 
No. in millions 
(percentage) 
No. in millions 
(percentage) 
African 804.9 (11.9) 5.888 (15) 20.407 (8.3) 26.295 (9.2) 
The Americas 915.4 (13.6) 3.211(8) 23.401 (9.5) 26.612 (9.3) 
Eastern 
Mediterranean 580.2 (8.6) 4.918 (12.5) 18.581 (7.6) 23.499 (8.2) 
European 889.2 (13.2) 2.713 (7) 25.502 (10.4) 28.215 (9.9) 
South-East Asian 
(India excluded) 579.1 (8.6) 3.974 (10.1) 23.938 (9.7) 27.913 (9.8) 
Western Pacific 
(China excluded) 442.3 (6.6) 2.338 (6) 12.386 (5) 14.724 (5.2) 
India 1181.4 (17.5) 8.075 (20.5) 54.544 (22.2) 62.619 (21.9) 
China 1344.9 (20) 8.248 (20.9) 67.264 (27.3) 75.512 (26.5) 
World 6737.5 (100) 39.365 (100) 246.024 (100) 285.389 (100) 
 
Globally, the major causes of blindness are cataract, glaucoma, age-related 
macular degeneration, and diabetic retinopathy (Figure 1-1) [4].  Diabetic retinopathy is a 
serious eye problem in the world, and also the most common diabetic eye disease.  It is 
the leading cause of blindness in working-aged adults in the United States and around the 
word [5, 6]. 
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Figure 1-1: Global causes of blindness due to eye diseases and uncorrected refractive 
errors [4].   
Diabetic eye disease refers to a group of eye problems that people with diabetes 
may face as a complication of diabetes, and all can cause severe vision loss or 
even blindness [7].  Diabetic eye disease may include diabetic retinopathy, cataract, and 
glaucoma.  Cataract is a clouding of the eye’s lens and develops at an earlier age in 
people with diabetes.  Glaucoma results from rise in fluid pressure inside the eye that 
leads to optic nerve damage and loss of vision.  A person with diabetes is nearly twice as 
likely to get glaucoma as other adults.  Diabetic retinopathy is caused by diabetes.  It 
affects the retina, the light-sensitive tissue at the back of the eye, and causes the most 
blindness in U.S. adults [5].  It affects the vision of more than half of the 18 million 
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people diagnosed with diabetes age 18 or older.  People with diabetes should have a 
complete eye exam through dilated pupils at least once a year. 
1.1.1 Stages	of	Diabetic	Retinopathy	
The retina is the light-sensitive tissue at the back of the eye.  A healthy retina is 
necessary for good vision.  Diabetic retinopathy is a gluocose-induced microvasuclar 
disease, leading to progressive damage to the tiny blood vessels that nourish the retina [8].  
The damaged blood vessels may swell and leak blood and other fluids, causing clouding 
of vision [9].  This circulation problems cause retinal tissue to become oxygen deprived, 
resulting in retinal hypoxia (i.e., lack of oxygen) and irreversible retinal nerve cell 
degeneration and death.  It is a serious sight-threatening complication of diabetes.  
Diabetic retinopathy usually affects both eyes, leading to significant vision loss if left 
untreated. 
Normal vision and the same scene viewed by a person with diabetic retinopathy 
are compared in Figure 1-2 [7]. 
 
  
(a)      (b) 
Figure 1-2: (a) Normal vision. (b) The same scene viewed by a person with 
diabetic retinopathy [7]. 
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Diabetic retinopathy has four stages or severity levels [7, 9, 10], which are 
summarized in Table 1-3 [10]: 
1. Mild Nonproliferative Diabetic Retinopathy (NPDR).  At this earliest stage, 
small areas of balloon-like bulges called microaneurysms may protrude from the 
walls of the retina’s tiny blood vessels. 
2. Moderate NPDR.  As the disease progresses, some blood vessels that nourish the 
retina are blocked. 
3. Severe NPDR.  Many more blood vessels are blocked, depriving several areas of 
the retina with their blood supply.   
4. Proliferative Diabetic Retinopathy (PDR).  At this advanced stage, the retina 
sends signals for nourishment, triggering the growth of new blood vessels that are 
abnormal and fragile.  The new blood vessels grow along the retina and toward 
the vitreous, the gel-like fluid that fills the inside of the eye.  They may leak blood 
into the vitreous, causing severe vision loss and blindness. 
Table 1-3: International Clinical Diabetic Retinopathy Disease Severity Scale [10]. 
Proposed disease 
severity level Findings observable upon dilated ophthalmoscopy 
Mild NPDR Microaneurysms only 
Moderate NPDR More than just microaneurysms but less than severe NPDR 
Severe NPDR 
No signs of PDR, with any of the following: 
1. More than 20 intraretinal hemorrhages in each of four 
quadrants 
2. Definite venous beading in two or more quadrants 
3. Prominent intraretinal microvascular abnormalities in 
one or more quadrants 
PDR Neovascularization and/or vitreous/preretinal hemorrhage 
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The classic retinal microvascular signs of nonproliferative diabetic retinopathy are 
microaneurysms, hemorrhages, hard exudates (lipid deposits), cotton wool spots 
(accumulations of axoplasmic debris within adjacent bundles of ganglion cell axons), 
venous dilation and beading, and intraretinal microvascular abnormalities (dilated pre-
existing capillaries; Figure 1-3). 
 
 
Figure 1-3: Non-proliferative diabetic retinopathy.  Cardinal signs are retinal 
microaneurysms, hemorrhages, and hard exudates (A and B); and intraretinal 
microvascular abnormalities (C, arrow); venous beading (D, arrow); and venous loop 
formation (E, arrow). 
The pathogenesis of PDR are schematically shown in Figure 1-4 [11]. 
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Figure 1-4: Retinal anatomy and mechanisms of proliferative diabetic retinopathy [11].  
A normal retina is shown in Panel A, and a retina from a patient with proliferative 
diabetic retinopathy is shown in Panel B.   
Several polypeptide growth factors and their cell-membrane receptors have 
possible relevance to the pathogenesis of diabetic retinopathy, but vascular endothelial 
growth factor (VEGF) and its receptors, VEGFR-1 and VEGFR-2, and pigment-
epithelium–derived factor (PEDF), for which no receptor has yet been identified, are 
currently undergoing the most intensive investigation [11].  These two growth factors are 
both produced in the retinal pigment epithelium, where their constitutive secretion 
appears to be highly polarized.  Retinal neovascularization in diabetic retinopathy nearly 
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always occurs away from the retinal pigment epithelium and toward the vitreous space.  
There is evidence that both VEGF and PEDF are produced in retinal neurons and in glial 
cells, such as the cells of Müller [11].  In the normal retina, VEGFR-1 is the predominant 
VEGF receptor on the surface of retinal vascular endothelial cells, but in diabetes, 
VEGFR-2 appears on the endothelial-cell plasma membrane (Figure 1-4) [11]. 
The appearance of retinal neovascularization is a hallmark of PDR (Figure 1-5) 
[12].  Fibrovascular proliferation is a characteristic of advanced proliferative disease. 
 
 
Figure 1-5: Proliferative diabetic retinopathy [12].  Neovascularization, a hallmark of 
proliferative diabetic retinopathy (A, arrows), which can be identified on fluorescein 
retinal angiogram (B, arrows); resolution of retinopathy with panretinal photocoagulation 
(C); progression of retinopathy without treatment to fibroproliferative disease (D). 
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1.1.2 Causes	of	Vision	Loss	and	Risk	Factors	
Blood vessels damaged from diabetic retinopathy can cause vision loss in 
two ways [7, 9]: 
1. Fluid can leak into the macula, the area of the retina that is responsible for sharp, 
clear, central vision and allows us to see colors and fine detail.  The fluid makes 
the macula swell, blurring vision.  This condition is called macular edema [13].  It 
can occur at any stage of diabetic retinopathy, although it is more likely to occur 
as the disease progresses.  About half of the people with proliferative diabetic 
retinopathy also have macular edema. 
2. Fragile, abnormal blood vessels can develop and leak blood into the center of the 
eye, blocking vision.  This is proliferative diabetic retinopathy and is the fourth 
and most advanced stage of the disease.  Other complications include detachment 
of the retina due to scar tissue formation and the development of glaucoma, an 
eye disease causing progressive damage to the optic nerve.  In cases of 
proliferative diabetic retinopathy, the cause of this nerve damage is extremely 
high pressure in the eye.  If left untreated, proliferative diabetic retinopathy can 
cause severe vision loss and even blindness. 
 
All people with diabetes–both type 1 and type 2–are at risk for the development of 
diabetic retinopathy.  The longer the patients have diabetes, the more likely they will 
develop diabetic retinopathy.  Between 40 to 45 percent of Americans diagnosed with 
diabetes have some stage of diabetic retinopathy [7, 14].  People with other medical 
conditions such as high blood pressure and high cholesterol are at greater risk [9].  
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Pregnant women face a higher risk for developing diabetes and diabetic retinopathy [15].  
If gestational diabetes develops, the patients are at much higher risk of developing 
diabetes as they age. 
Everyone with diabetes is recommended to get a comprehensive dilated eye 
examination at least once a year, since macula edema and proliferative diabetic 
retinopathy can develop without symptoms, such that patients are at high risk for 
vision loss.   
1.1.3 Symptoms	
Often there are no visual symptoms in the early stages of diabetic retinopathy.  In 
the later stages, symptoms of the disease may include [9]: 
1. Blurred vision.  Prolonged periods of high blood sugar can lead to the 
accumulation of fluid at the lens inside the eye that controls eye focusing.  This 
changes the curvature of the lens and results in the development of symptoms of 
blurred vision.  Blurred vision may also occur when the macula (i.e., the part of 
the retina that provides sharp central vision) swells from leaking fluid. 
2. Seeing spots or floaters in the field of vision.  If new blood vessels grow on the 
surface of the retina, they can bleed into the eye and block vision.  When the 
bleeding occurs, patients will see a few specks of blood, or spots, “floating” in the 
field of vision.  If spots occur, patients should see an eye care professional as soon 
as possible.  They may need treatment before more serious bleeding occurs.  
Hemorrhages tend to happen more than once, often during sleep.  If left untreated, 
proliferative diabetic retinopathy can cause severe vision loss and even blindness.   
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1.1.4 Diagnosis	and	Detection	
Diabetic retinopathy and macular edema can be detected through a comprehensive 
eye examination that includes [7, 9]: 
1. Visual acuity test.  This eye chart test determines the extent to which central 
vision has been affected. 
2. Dilated eye exam.  Drops are placed in eyes to widen, or dilate, the pupils.  This 
allows the eye care professional to see more of the inside of eyes to check for 
signs of the disease.  The eye care professional uses a special magnifying lens to 
examine the retina and optic nerve for signs of damage and other eye problems.   
3. Tonometry.  An instrument measures the pressure within the eye.  Numbing 
drops may be applied to eyes for this test. 
 
The eye care professional checks the retina for early signs of the 
disease, including [7]: 
1. Leaking blood vessels. 
2. Retinal swelling (macular edema). 
3. Pale, fatty deposits on the retina (signs of leaking blood vessels). 
4. Damaged nerve tissue. 
5. Any changes to the blood vessels. 
 
Supplemental testing may include fluorescein angiography [7, 9, 16].  In this test, 
a special dye is injected into the arm, and pictures are taken as the dye passes through the 
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blood vessels in the retina.  The test allows the evaluation and identification of any 
abnormal blood vessel growth and leaking blood vessels. 
1.2 Current Treatments of Diabetic Retinopathy 
Treatment of diabetic retinopathy depends on the stage of the disease.  During the 
first three stages of diabetic retinopathy, no treatment is needed, unless macular edema 
occurs.   
1.2.1 Laser	Surgery	
If the disease advances, leakage of fluid from blood vessels can lead to macular 
edema, which is treated with laser surgery.  This procedure is called focal laser treatment 
(photocoagulation) [7, 9].  Up to several hundred small laser burns are created in areas of 
the retina with abnormal blood vessels to try to seal the leaks and reduce the amount of 
fluid in the retina.  A patient may need focal laser surgery more than once to control the 
leaking fluid.   
When blood vessel growth is more widespread throughout the retina, as in 
proliferative diabetic retinopathy, a laser surgery called scatter laser treatment is needed 
[7, 17].  1,000 to 2,000 scattered laser burns are created in the areas of the retina away 
from the macula, causing the abnormal blood vessels to shrink and disappear.  Because a 
high number of laser burns are necessary, two or more sessions usually are required to 
complete treatment.  With this procedure, peripheral vision may be partially lost in order 
to preserve central vision.  Scatter laser treatment may slightly reduce color vision and 
night vision. 
13 
 
1.2.2 Vitrectomy	
In more advanced cases such as severe bleeding, a surgical procedure called a 
vitrectomy may be needed to restore sight by removing significant amount of blood from 
the center of the eye (vitreous gel) [7, 18].  Retinal detachment, defined as separation of 
the light-receiving lining in the back of the eye, resulting from diabetic retinopathy, may 
also require surgical repair [9]. 
A vitrectomy is performed under either local or general anesthesia.  A doctor 
makes a tiny incision in the eye of a patient.  Next, a small instrument is used to remove 
the vitreous gel that is clouded with blood and replace it with a salt solution to maintain 
the normal shape and health of the eye.  Since the vitreous gel is mostly water, the patient 
will notice no change between the salt solution and the original vitreous gel.  The 
patient’s eye will be red and sensitive.  The patient will need to wear an eye patch for a 
few days or weeks to protect the eye, and also need to use medicated eyedrops to protect 
against infection.   
1.2.3 Anti‐VEGF	Therapy	
Anti-VEGF therapies are important in the treatment of diabetic retinopathy.  They 
can involve monoclonal antibodies such as bevacizumab, antibody derivatives such 
as ranibizumab, or orally-available small molecules that inhibit the tyrosine 
kinases stimulated by VEGF [19].  Both antibody-based compounds are commercialized.  
The efficacy of treatment with the anti-VEGF agents ranibizumab and 
bevacizumab indicates that VEGF contributes to the pathogenesis of diabetic macular 
edema and reflects successful translational research. 
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1.2.4 Severe	Drawbacks	of	Current	Treatments	
Although current treatments of diabetic retinopathy (i.e., laser treatment, 
vitrectomy surgery and anti-VEGF therapy) can reduce vision loss, they only slow down 
but cannot stop the degradation of the retina.  Patients require repeated treatment to 
protect their sight.  Once some people develop proliferative diabetic retinopathy, they 
will always be at risk for new bleeding. 
The current treatments also have significant drawbacks.  Laser therapy is focused 
on preserving the macula, the area of the retina that is responsible for sharp, clear central 
vision, by sacrificing the peripheral retina since there is only limited oxygen supply.  
Therefore, laser therapy results in a constricted peripheral visual field, reduced color 
vision, delayed dark adaptation, and weakened night vision [20].  Vitrectomy surgery 
increases the risk of neovascular glaucoma, another devastating ocular disease, 
characterized by the proliferation of fibrovascular tissue in the anterior chamber angle 
[21].  Anti-VEGF agents have potential adverse effects, and currently there is insufficient 
evidence to recommend their routine use. 
1.2.5 Proposed	Oxygen	Therapy	
In this work, for the first time, a paradigm shift in the treatment of diabetic 
retinopathy is proposed: providing localized, supplemental oxygen to the ischemic tissue 
via an implantable MEMS device. 
The retinal architecture (e.g., thickness, cell densities, layered structure, etc.) of 
the rabbit eye exposed to ischemic hypoxic injuries was well preserved after targeted 
oxygen delivery to the hypoxic tissue, showing that the use of an external source of 
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oxygen could improve the retinal oxygenation and prevent the progression of the 
ischemic cascade (Figure 1-6) [22].   
 
 
Figure 1-6: Hematoxylin and eosin–stained vertical retinal sections from the region 4 disc 
diameters below the optic disc, comparing the retinal histology 2 weeks after retinal 
ischemia [22].  The no treatment eye shows reduced retinal thickness, disorganization, 
and loss of inner and outer nuclear layers (INL, ONL), loss of inner and outer segments 
(IS, OS) of the photoreceptors, vacuolization of the ganglion cell layer (GCL), and cell 
loss and pigment clumping of the RPE.  In contrast, the oxygenated eye shows good 
retinal thickness and well-preserved anatomy compared with the contralateral 
nonoperated normal rabbit eye.  The RPE/choroid is shown at higher magnification in the 
lower panels.  There is prominent choroidal atrophy in the non-treated group, whereas the 
oxygenated group shows only mild atrophy of the choroidal vasculature.  Scale bar, 
20µm. 
The proposed MEMS device transports oxygen from an oxygen-rich space to the 
oxygen-deficient vitreous, the gel-like fluid that fills the inside of the eye, and then to the 
ischemic retina.  This oxygen transport process is purely passive and completely driven 
by the gradient of oxygen partial pressure (݌ܱଶ).  Two types of devices were designed.  
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For the first type, the oxygen-rich space is underneath the conjunctiva, a membrane 
covering the sclera (white part of the eye), beneath the eyelids and highly permeable to 
oxygen in the atmosphere when the eye is open.  Therefore, sub-conjunctival ݌ܱଶ is very 
high during the daytime.  For the second type, the oxygen-rich space is inside the device 
since pure oxygen is needle-injected into the device on a regular basis. 
The proposed MEMS oxygen transporter devices can be also applied to treat other 
ocular and systemic diseases accompanied by retinal ischemia, such as central retinal 
artery occlusion, carotid artery disease, and some form of glaucoma.   
1.3 Ideal Materials for Medical Implants 
1.3.1 Parylene	
Parylene is the trade name for a variety of chemical vapor deposited poly(p-
xylylene) polymers [23].  The chemical structures of major types of parylene polymers 
are shown in Figure 1-7.  Parylenes have been widely used for coating medical devices 
such as stents, defibrillators, pacemakers, and other devices permanently implanted into 
the body due to its USP (U.S. Pharmacopeia) class VI (highest class) biocompatibility, 
good barrier properties, good chemical and corrosion resistance, stability to oxidation, 
low intrinsic thin film stress (for its room temperature deposition), and very low 
permeability to gases [23].  Parylenes have a Young’s modulus of 2.8-4GPa and high 
malleability such that they can withstand up to 200% elongation.  They are also optically 
transparent and enable the optical detection.  Parylenes are usually prepared by the 
chemical vapor deposition at room temperature, and form pinhole-free, conformal, and 
completely homogeneous films.  Those films are also machinable by fabrication 
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processes compatible with CMOS/MEMS technologies, such as photolithography and 
oxygen plasma dry etching.   
 
      Parylene C        Parylene D           Parylene N           Parylene HT 
 
Figure 1-7: The chemical structures of major types of parylene polymers 
Among them, parylene C or poly(chloro-para-xylylene) is the most popular type 
because of its combination of excellent moisture barrier properties, cost, and accessible 
processing techniques.  These advantages make parylene C a most popular choice for 
medical implants.  The parylene C vacuum deposition process is illustrated in Figure 1-8.  
First, the powered parylene C raw dimer is vaporized at about 150°C, then the dimeric 
gas molecules are pyrolyzed at about 690°C and cleaved to monomer form.  The 
chemically unstable and reactive monomer gas is subsequently introduced into an 
evacuated deposition chamber where it disperses and polymerizes spontaneously on 
substrate surfaces to form conformal films [24]. 
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Figure 1-8: The parylene C vacuum deposition process [24]. 
The deposition temperature is usually room temperature (20°C), and the 
deposition pressure is in the range of 20–100mTorr.  In this dissertation, we will study 
the effects of modification of deposition temperature on the physical properties of 
parylenes C, D, N, and HT, and study the deposition kinetics both experimentally and 
theoretically.   
1.3.2 Silicone	
Silicone is a family of inert and synthetic polymer compounds made up of 
repeating units of siloxane, which is a functional group in organosilicon chemistry with 
the Si–O–Si linkage [25], shown in Figure 1-9 [26].  Silicone polymers are typically heat-
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resistant and rubber-like, and exhibit many useful characteristics, including low thermal 
conductivity, low chemical reactivity, low toxicity, thermal stability (constancy of 
properties over a wide temperature range of −100 to 250°C), the ability to repel water and 
form watertight seals, good biocompatibility, resistance to oxygen, ozone, and ultraviolet 
(UV) light, the ability to be formulated to be either electrically insulative or conductive, 
and high gas permeability [25].  These properties have led to widespread use of silicones 
in sealants, adhesives, lubricants, plumbing and building construction, cooking utensils, 
microfluidics, thermal and electrical insulation, personal care, and medicine [25].  The 
most important properties of silicone to our MEMS medical devices are its high 
biocompatibility and durability, which make it a popular material for medical 
applications.  For example, silicone is widely used in bandages and dressings, breast 
implants, testicle implants, pectoral implants, contact lenses, and scar treatment sheets 
[25].  It also has many medical uses in ophthalmology, such as silicone oil used to replace 
the vitreous following vitrectomy, silicone intraocular lenses following cataract 
extraction, silicone tubes to keep nasolacrimal passage open following 
dacrycystorhinostomy, canalicular stents for canalicular stenosis, punctal plugs for 
punctal occlusion in dry eyes, silicone rubber and bands as an external temponade in 
tractional retinal detachment, and anteriorly located break in rhegmatogenous retinal 
detachment [25].  At room temperature, the permeability of silicone rubber for gases such 
as oxygen is approximately 400 times that of butyl rubber, making silicone useful for 
medical applications in which increased aeration is desired [25].  Polydimethylsiloxane 
(PDMS) belongs to the group of silicone, and is often used for medical purpose.  The 
chemical structure of PDMS is shown in Figure 1-9 [27]. 
20 
 
 
  
   Siloxane           PDMS 
Figure 1-9: The chemical structure of the siloxane functional group [26], and the 
polydimethylsiloxane (PDMS) that belongs to the group of silicone [27]. 
1.4 Layout of the Dissertation 
This dissertation focuses on the design, fabrication, testing, and applications of 
MEMS materials and devices for developing novel therapies for diabetic retinopathy.  In 
Chapter 1, after a brief introduction of pathology of diabetic retinopathy, the ideal and 
optimal treatment of retinal ischemia by targeted oxygen delivery is discussed and the 
concept of an oxygen transporter device is defined.  The device materials parylene and 
silicone, and the major processes and techniques for the two materials are then briefly 
reviewed.  Without deep understanding of the properties of parylene and silicone, the 
MEMS oxygen transporter device would not be successful.  Chapter 2 will focus on the 
material studies of parylene and silicone, including their mechanical properties, 
rheological properties, permeability, and interface adhesion.  The material properties 
studied in Chapter 2 will provide solid practical ways to achieve the optimized 
performance of the device.  In Chapter 3, two types of oxygen transporter devices will be 
described and discussed in detail.   
 
21 
 
CHAPTER 2 STUDY OF 
PAYRLENE AND 
SILICONE 
2.1 Overview 
This chapter reports the study of in-situ deposition temperature (ranging from 
20°C to 80°C) effects on the physical properties of parylene C in terms of glass transition 
temperature ( ௚ܶ ), β-relaxation temperature ( ఉܶ ), Young’s modulus, and crystallinity 
(including crystallite size).  The parylene C thin film deposited at higher deposition 
temperature exhibited higher ௚ܶ  and ఉܶ , revealing that the movement of molecular 
backbones was further frozen and restricted.  It was consistent with the findings that 
higher deposition temperature induced greater degree of crystallinity and larger Young’s 
modulus.  With the new knowledge, parylene C thin film with properties tailored to 
various requirements could be achieved by choosing the appropriate deposition 
temperature.   
The deposition of parylene onto silicone was also investigated thoroughly.  PDMS 
is the most widely used silicon-based organic polymer, belonging to a group of polymeric 
organosilicon compounds that are commonly referred to as silicones.  Its applications 
range from contact lenses and medical devices to elastomers; it is also present in 
shampoos (as dimethicone makes hair shiny and slippery), food (antifoaming 
agent), caulking, lubricants, and heat-resistant tiles.  The study of mechanical behaviors 
22 
 
and barrier properties of the hybrid parylene/PDMS material is lacking.  The repetitive 
uniaxial tensile tests were performed to characterize its mechanical behaviors and the 
water vapor transmission rate was measured to evaluate its barrier properties.  The 
experimental data were in very good accordance with the composite material theory.  A 
novel approach of facilitating the diffusion and penetration of parylene coatings into 
PDMS using in-situ heated deposition is presented.  The parylene depth profiling in 
PDMS was produced using the second ion mass spectroscopy, and 180° peel tests were 
implemented using a commercial tensile testing equipment, both demonstrating that in-
situ heated parylene deposition enhanced the pore sealing capability of parylene.  A 
theoretical deposition model was proposed, featuring a cylindrical PDMS pore model, a 
free molecular flow (Knudsen flow) model, and chemisorption deposition kinetics.  There 
was only one unknown parameter in the model, that is, the PDMS pore diameter.  By 
fitting the experimental parylene depth profiling curves to the nonlinear theoretical 
deposition model, the PDMS pore diameter was estimated to be about 6nm.   
The penetration properties of various parylenes into long microfluidic channels 
were then studied.  The work broadly covered the effects of the dimer type (i.e., 
parylenes C, N, and HT), loaded dimer mass, substrate temperature, and channel size on 
the penetration length of parylene into the microfluidic channel.  Understanding the 
mechanism underlying parylene penetration into microchannels helps to design and 
develop the mass-producible inner surface protection process for microfluidic devices. 
Finally, one application of parylene and silicone in microfluidics is presented, 
which is a capillary pressure-driven viscometer.  This viscometer demanded small 
amount of samples, provided fast measurement, and produced a wide range of shear rates 
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during a single run.  After the device calibration with water, the viscosity measurement of 
human whole blood resulted in very good agreement with the published data, 
demonstrating the reliability of the device.  The first experimental study on the non-
Newtonian viscosity of adult zebrafish whole blood was also produced using this 
viscometer, and the whole blood viscosity of zebrafish was found smaller than that of 
human, likely attributed to the smaller hematocrit for zebrafish blood. 
2.2 Effects of Deposition Temperature on Parylene Properties 
Parylene C has been widely utilized as protective coating for microelectronic 
devices due to its exceptional properties such as conformal deposition, low dielectric 
constant, low moisture permeability and chemical stability.  It has also become a well-
known material for biomedical implants due to its superior biocompatibility [28].  
Therefore it is important to fundamentally understand and then hopefully improve the 
physical properties of parylene C for better device performance and longer-term 
consistency. 
People have conducted research on many aspects of parylene’s properties such as 
auto-fluorescence [29], permeability [30], and surface hydrophobicity [31].  It is of great 
significance to study the techniques of tuning the material properties for various 
applications by elucidating the correlation between structure and property.  Thermal 
treatment proves an effective way of modifying the properties of many materials such as 
CVD deposited silicon nitride [32], as well as parylene.  However, for parylene C, so far 
most studies have been focused on post-deposition thermal treatment, rather than in-situ 
thermal treatment.  For example, thermal annealing posterior to deposition was found to 
alter the crystallinity of parylene C [33].  Unfortunately, post-deposition thermal 
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treatment of parylene C has significant disadvantages.  For example, annealing of 
parylene in the air over 120ºC can cause oxidation-induced brittleness to the film, which 
is detrimental to the robustness of parylene.  The deposition temperature effects on the 
properties of parylene have not been well scrutinized since parylene is conventionally 
prepared by chemical vapor deposition (CVD) process at room temperature.  We have 
previously found that parylene-on-parylene adhesion could be enhanced by increasing the 
in-situ deposition temperature [34].  Therefore it is intriguing to further investigate the 
effects of deposition temperature on other aspects, such as the viscoelastic properties of 
parylene.  Glass transition (also called ߙ-relaxation) is the primary relaxation process in 
amorphous polymers, associated with the cooperative segmental motions of the polymer 
backbone.  The physical properties of polymers such as mechanical, electrical, and 
optical properties may be a strong function of glass transition temperature ( ௚ܶ ), and 
change abruptly at ௚ܶ .  Polymers with amorphous phase can also exhibit a lower-
temperature relaxation process usually referred to as the ߚ-relaxation process.  This has 
been suggested to be associated with the localized conformational motion of the chain 
section of the size comparable with the Kuhn’s segment (the correlation part of the chain) 
[35].  It merges with the glass transition at temperatures somewhat above ௚ܶ.   
We first implemented the in-situ heating capability of depositing parylene C thin 
films at elevated temperatures and then measured the ௚ܶ and the ߚ-relaxation temperature 
( ఉܶ) using dynamic mechanical analysis (DMA) and dielectric/impedance spectroscopy, 
respectively.  The film crystallinity was studied by X-ray diffraction (XRD), and the 
uniaxial tensile tests were performed to measure the Young’s modulus.  Finally, all the 
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measurement data were summarized, including comparisons between thin films deposited 
at different temperatures.   
2.2.1 Sample	Preparation	
The in-situ heating setup for parylene C deposition at elevated temperatures is 
schematically shown in Figure 2-1.  Parylene C film was deposited onto a fresh silicon 
wafer while the silicon substrate was heated up during the deposition.  The feedback from 
the heater based on a temperature sensor assisted in the adjustment of the power through 
a thermal controller to maintain the setting point.  Four setting points of temperatures 
were chosen, which were 20°C (room temperature, thus not necessarily using the in-situ 
heating capability), 40°C, 60°C, and 80°C.   
 
 
Figure 2-1: The experimental setup for the in-situ heated deposition to prepare parylene C 
deposited at elevated temperatures.     
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Because of the exponential decay of deposition rate with deposition temperature 
[34], it took much longer time to accumulate thickness at higher deposition temperature.  
So the 20°C and 40°C samples had thicknesses of about 9µm, while the 60°C and 80°C 
samples were about 3µm in thickness.  Nevertheless, comparisons can still be made 
regardless of different thicknesses because the physical properties studied here are almost 
thickness-independent [36]. 
 
2.2.2 Experiments,	Testing	Results	and	Discussion	
2.2.2.1 DMA Tests 
Dynamical mechanical analysis (DMA) was performed using a commercial 
analytical instrument (DMA Q800, TA Instruments) to measure ௚ܶ.  The uniaxial tensile 
tests were also produced with the same instrument.  For DMA and uniaxial tensile tests, 
parylene C films were cut into strips with a width of 5.8mm and a length of 8mm.  Figure 
2-2 shows the plots of the storage modulus ܧ′  in response to the applied sinusoidal 
oscillation of the strain at 1Hz versus the measurement temperature ܶ for the 20°C, 40°C, 
60°C, and 80°C samples. 
For the DMA analysis, the storage modulus ܧ′ characterizes the elastic response 
of the polymer.  As the heating process proceeds such that the temperature reaches ௚ܶ, the 
physical properties change drastically as the material goes from a hard glassy state to a 
rubbery state.  Polymer backbone chains in the amorphous regions begin to coordinate 
large-scale cooperative segmental motions.  The energy loss due to internal friction and 
viscous motions is increased and the storage modulus undergoes a rapid decrease.  The 
glass transition temperature ௚ܶ  measured from the plot of ܧ′  versus the measurement 
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temperature ܶ is denoted as ܶ௚_ாᇲ, which is determined from the major inflection point on 
the ܧᇱ-ܶ curve, 
 
݀ଶܧ′
݀ܶଶ ቤ்ୀ்೒_ಶᇲ
ൌ 0. (2-1)
        
 
Figure 2-2: The DMA data of storage modulus ܧ′ vs. measurement temperature ܶ at 1Hz 
for parylene C deposited at 20-80°C (ܶ௚_ாᇲ corresponds to the major inflection point of 
each curve). 
Parylene C is a semi-crystalline polymer consisting of crystalline region and 
amorphous phase.  The increase in ௚ܶ with increased deposition temperature is apparent 
from Figure 2-2, which indicates that higher deposition temperature induces the growth 
of crystalline phase, resulting in smaller percentage of amorphous phase.  The ܧᇱ -ܶ 
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curves for 9µm-thick films are a little bit higher than those for 3µm-thick films since the 
elastic modulus increases slowly with thickness. 
2.2.2.2 Dielectric Measurement 
The impedance spectroscopy was used to perform the dielectric measurement.  
The 20°C, 40°C, 60°C, and 80°C parylene C samples were sandwiched between 
electrically conductive silver pastes that were dried at room temperature.  Thus the 
undesired thermal effects from the conventional metal deposition process could be 
prevented.   
The impedance of a material is complex in nature,  
 ܼ∗ ൌ ܼᇱ െ iܼ", (2-2)
where ܼ∗ is the complex impedance, and ܼ′ and ܼ" denote the real part and the negative 
imaginary part of the complex impedance ܼ∗, respectively. 
 From the measurement of the complex impedance, we can derive the complex 
relative permittivity ߝ∗ of parylene, 
 ߝ∗ ൌ 1i2ߨ݂ܥ଴ܼ∗, (2-3)
 ܥ଴ ൌ ߝ଴ܵ݀ , (2-4)
where ݂ is the measurement frequency, ܥ଴ is the equivalent capacitance of the free space, 
ߝ଴ is the vacuum permittivity, 8.85×10-12 F/m, and ܵ and ݀ are the surface area and the 
thickness of  parylene C film, respectively.   
We denote the real part and the negative imaginary part of the complex relative 
permittivity ߝ∗ as ߝᇱ and ߝ", respectively, 
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 ߝ∗ ൌ ߝᇱ െ iߝ". (2-5)
Based on eqns. (2-3) - (2-5), we can derive the following formulas for ߝᇱ and ߝ", 
 ߝᇱ ൌ ܼ"2ߨ݂ܥ଴ሺܼ′ଶ ൅ ܼ"ଶሻ, (2-6)
 ߝ" ൌ ܼ′2ߨ݂ܥ଴ሺܼ′ଶ ൅ ܼ"ଶሻ. (2-7)
ߝᇱ is also called the dielectric constant.  Figure 2-3 shows the plots of ߝᇱ versus 
the measurement temperature ܶ for parylene C samples.   
 
 
Figure 2-3: The dielectric measurement of ܶఉ_ఌᇲ of parylene C deposited at 20-80°C: the 
real part of the complex permittivity ߝ′ vs. measurement temperature ܶ  at 100Hz and 
10KHz, respectively. 
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ܶఉ_ఌᇲ  denotes the ߚ -transition temperature ఉܶ  measured from the ߝᇱ -ܶ  curve, 
determined from the major inflection point on the ߝᇱ-ܶ curve, 
 
݀ଶߝ′
݀ܶଶቤ்ୀ்ഁ_ಶᇲ
ൌ 0. (2-8)
The ߚ-relaxation mechanism for parylene C is that ߝᇱ is low below ܶఉ_ఌᇲ since the 
rotational motion and the orientation polarization of C-Cl dipoles are restricted, with a 
big increase around ܶఉ_ఌᇲ [37].   
For a higher deposition temperature, ఉܶ was also increased for both measurement 
frequencies, indicating that the thermal energy required for the activation of large 
localized C-Cl bond motions was increased as a result of more stabilized molecular 
arrangement and conformation.  The higher-frequency curves are to the right and the 
bottom of the lower-frequency curves, because at a high frequency, the polar C-Cl bond 
has less time to align with the external electric field, so that the dielectric constant is 
smaller and the ߚ-relaxation occurs at a higher temperature. 
2.2.2.3 XRD Tests 
The film crystallinity was studied by X-ray diffraction (XRD) using a 
diffractometer (Philips X’Pert PRO MRD Diffractometer).   
The XRD spectra with the 2ߠ ranging from 10° to 18° are presented in Figure 2-4.  
The XRD spectra show peaks at 2ߠ equal to about 14º for all tested samples.  The peak 
has been suggested to correspond to the (020) crystal plane [33].  The crystallite size ܦ is 
calculated using the Scherrer’s formula, 
 ܦ ൌ 0.9ߣܤcosߠ, (2-9)
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where ߣ is the wavelength of the X-ray beam, 1.5406 Å, ߠ is the Bragg angle, and ܤ is 
the full width at half maximum (FWHM) of the peak.   
 
 
Figure 2-4: The XRD spectra for parylene C samples deposited at 20-80°C.  The peak 
represents (020) plane of the monoclinic unit cell.   
A decrease in the FWHM of the XRD peak with the increased deposition 
temperature could be attributed to a large increase in the crystallite size according to the 
Scherrer’s formula in eqn. (2-9), as a result of the increasingly ordered polymeric chains 
due to the greater energy available for the chain motions and crystallization.  The 
interplanar spacing (݀-spacing), the crystallite size, the Bragg angles and the FWHM of 
the peak for samples deposited at different temperatures are summarized in Table 2-1.   
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2.2.2.4 Uniaxial Tensile Tests 
 
 
Figure 2-5: The uniaxial tensile test results of parylene C films at a strain loading rate of 
1%/min.  The Young's modulus ܧ is thickness-dependent, so the results for 3µm-thick 
films deposited at 20ºC, 60ºC and 80ºC are grouped on the top, and the results for 9µm-
thick films deposited at 20ºC and 40ºC grouped at the bottom.   
The stress-strain curves were obtained from the uniaxial tensile tests.  Due to the 
viscoelastic nature of parylene polymers, the stress-strain curves are rate-dependent (or 
frequency-dependent), so it is important to fix the strain ramping rate for all tests.  The 
strain loading rate was set to be 1%/min for all tensile tests.  The stress-strain curves for 
the 20°C, 40°C, 60°C, and 80°C parylene C samples are shown in Figure 2-5.  At least 
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four samples prepared in the same condition were tested, and the results were averaged.  
The Young’s modulus was determined from the slope of the elastic linear section of a 
stress-strain curve, which was after an initial toe region and before the yielding point.  
The Young's modulus ܧ is thickness-dependent, so the groups of stress-strain curves for 
3µm-thick and 9µm-thick films are shown on the top and at the bottom of Figure 2-5, 
respectively. 
The crystalline phase of parylene C features strong interactions between 
conjugated aromatic rings and thus a high elastic modulus.  When the crystallites formed 
by ordered chains grow larger and larger, more phenyl groups are involved in the 
strongly attractive intermolecular interaction.  So the greater Young’s modulus is also a 
result of the higher degree of crystallization.   
2.2.2.5 Discussion 
The results of the ௚ܶ, the ఉܶ, the XRD scanning data, and the Young’s modulus ܧ 
for parylene C samples deposited at 20ºC, 40ºC, 60ºC, and 80ºC are summarized in Table 
2-1 and  
Table 2-2.  It is experimentally shown that at a higher deposition temperature, the 
parylene C polymer is thermodynamically driven for higher degree of crystallization with 
larger crystallite sizes, thus ending up with a lower energy state.  The increase in the 
degree of crystallinity reduces the percentage of amorphous disordered polymer chains 
and results in more stable conformation.  Hence, molecular chains are more spatially 
immobilized and harder for stretching deformation, leading to a larger Young’s modulus.  
Polymer segmental motion is a strong function of temperature, and polymer with a 
greater degree of crystallinity needs more thermal energy to overcome intermolecular 
34 
 
interaction barriers to achieve sufficient segmental motion for conformational transition, 
resulting in higher ௚ܶ and ఉܶ.  Based on these new data, we conclude that it is possible to 
tailor parylene C’s properties to specific requirements by choosing the right deposition 
temperature.  For example, depositing parylene C at a higher temperature gives a higher 
௚ܶ so that the film can operate at higher temperature without additional annealing, which 
can avoid the undesired oxidation of parylene C and the significant degradation of the 
mechanical properties.   
Table 2-1: The summary of the XRD results for parylene C samples deposited from 20°C 
to 80°C. 
Deposition 
Temperature (°C) °૛ࣂ	 FWHM (°૛ࣂ) ࢊ-spacing (Å) Crystallite size (Å) 
20 14.07 1.19 6.29 67.3 
40 13.92 0.91 6.36 88.0 
60 13.89 0.73 6.37 109.7 
80 13.98 0.65 6.33 123.2 
 
Table 2-2: The summary of the ௚ܶ , the ఉܶ , and the Young's modulus for parylene C 
samples deposited from 20°C to 80°C. 
Deposition 
temperature (°C) 
Thickness 
(µm) 
ࢀࢍ_ࡱᇲ (°C) 
@1Hz 
ࢀࢼ_ࢿᇲ(°C) Young’s modulus ࡱ
(GPa) at a strain 
rate of 1%/min 100Hz 10KHz 
20 9 52.7 50.2 72.1 2.90 
40 9 61.2 55.4 79.8 3.01 
20 3 N/A 2.59 
60 3 88.8 63.8 90.2 2.80 
80 3 103.1 68.8 97.8 2.98 
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2.3 Hybrid Parylene/PDMS Material 
Parylene is widely used in various industries because of its many excellent 
properties, such as the superior barrier property used to protect electronic devices against 
damages from moisture and corrosive etchants [38-40].  The hybrid parylene/PDMS 
material has also been investigated, such as parylene-caulked PDMS [41, 42] and 
parylene coatings inside PDMS microchannels [43], attempting to take advantage of the 
excellent barrier property of parylene.  However, the mechanical behavior such as the 
uniaxial tensile stress-strain relation and the barrier property such as the water vapor 
transmission rate (WVTR) of the hybrid parylene/PDMS material have not been well 
documented.  The understanding of these properties will be very important to the design 
and the application of this hybrid parylene/PDMS material. 
The pore-sealing feature of parylene conformal coating has been utilized to 
reduce gas or moisture permeation through various porous materials.  For examples, 
parylene-caulked PDMS was tested, as a potential material for long-term pneumatic 
balloon actuator [41], and parylene coatings onto porous ultralow-k interlayer dielectrics 
were used to prevent precursor penetration during subsequent metallorganic deposition 
[44].  However, these demonstrations only used parylene deposition at room temperature 
(RT).  In-situ heated deposition has led to the thorough investigation of deposition 
temperature effects on thermal, structural, and mechanical properties of parylene C [45].  
This section presents another application of in-situ heated parylene deposition, which is 
improving the diffusion and penetration of parylene into the bulk PDMS.  The hypothesis 
is that the surface mobility of parylene monomer is a strongly increasing function of 
temperature such that the gaseous monomer tends to diffuse further inside the PDMS 
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pore at elevated deposition temperatures.  The enhanced pore sealing capability of 
parylene at elevated deposition temperatures was verified by experiments.   
2.3.1 Mechanical	Behavior	
 
 
(a) 
 
 
(b) 
Figure 2-6: (a) The stress-strain relations for six successive uniaxial tensile tests of 
parylene/PDMS samples before RIE etching.  (b) Stress-strain relations for three 
successive uniaxial tensile tests of parylene/PDMS samples after RIE etching.  0.3µm-
thick surface PA-C was etched away. 
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In order to investigate the mechanical behavior of the hybrid parylene/PDMS 
material, we first prepared 92µm-thick PDMS (Sylgard 184, Dow Corning, base:curing 
agent=10:1 by weight, cured at 70°C for 75min) samples coated with 0.64µm-thick 
parylene C (PA-C).  Reactive ion etching (RIE) was performed to etch away 0.3µm-thick 
surface PA-C of the samples.  Reiterated uniaxial tension tests were performed using a 
commercial tensile testing machine (DMA Q800, TA Instruments). 
In each iteration, the sample was loaded till the strain ߝଵ  was reached, then 
relaxed, preparing for the subsequent loading till the strain ߝଶ > ߝଵ was reached.  Stress-
strain relations for the hybrid parylene/PDMS samples before and after the RIE etching 
are shown in Figure 2-6. 
2.3.2 Barrier	Property	
The WVTR was measured using a commercial water vapor permeability tester 
(TSY-W3, Labthink).  Samples included pure PDMS, and PDMS coated with 0.64µm-
thick PA-C before and after RIE etching.  In the case of RIE etching, either 0.3µm-thick 
or 0.64µm-thick surface PA-C was etched away.  The thickness of PDMS was 92µm.  
Thermal annealing treatments at two different temperatures, 80°C in a convection oven 
and 180°C in a vacuum oven, for 8 hours were performed to study the thermal annealing 
effect on the WVTR of the samples.  The WVTR experimental data (Figure 2-7) show 
that the thermal annealing treatment could decrease the WVTR of the hybrid 
parylene/PDMS.  The reason is likely that the high temperature annealing can decrease 
the WVTR of parylene by increasing its crystallinity and decrease the WVTR of PDMS 
by increasing its degree of cross-linking. 
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Based on the composite material theory, the Young’s modulus of the hybrid 
parylene/PDMS material ܧ௛௬௕௥௜ௗ is given by the “rule of mixtures”, 
 ܧ௛௬௕௥௜ௗ ൌ ܧ௉஺஼ݐ௉஺஼ݐ௉஺஼ ൅ ݐ௉஽ெௌ ൅
ܧ௉஽ெௌݐ௉஽ெௌ
ݐ௉஺஼ ൅ ݐ௉஽ெௌ, (2-10)
and the WVTR of the hybrid material  ܹܸܴܶ௛௬௕௥௜ௗ is given by, 
 
1
ܹܸܴܶ௛௬௕௥௜ௗ ൌ
1
ܹܸܴܶ௉஺஼ ൅
1
ܹܸܴܶ௉஽ெௌ, (2-11)
where ܧ௉஺஼ , ܹܸܴܶ௉஺஼ , and ݐ௉஺஼  are the Young’s modulus, the WVTR, and the 
thickness of PA-C, respectively, and ܧ௉஽ெௌ , ܹܸܴܶ௉஽ெௌ , and ݐ௉஽ெௌ  are the Young’s 
modulus, the WVTR, and the thickness of PDMS, respectively. 
 
 
Figure 2-7: The WVTR experimental data for various parylene/PDMS samples with and 
without annealing.  A: 92µm-thick PDMS; B: 92µm-thick PDMS coated with 0.64µm-
thick PA-C; C: 92µm-thick PDMS coated with 0.64µm-thick PA-C, followed by RIE to 
etch away 0.3µm-thick surface PA-C; and D: 92µm-thick PDMS coated with 0.64µm-
thick PA-C, followed by RIE to etch away all the surface PA-C. 
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The experimental data of the Young’s modulus and the WVTR of parylene, 
PDMS and the hybrid parylene/PDMS material are summarized in Table 2-3, and the 
theoretical results of the Young’s modulus and the WVTR of the hybrid material are 
summarized in Table 2-4.  Here, the experimental result of the Young’s modulus of the 
hybrid parylene/PDMS is calculated from the stress-strain curve for the first iteration in 
the repeated uniaxial tensile test run. 
Table 2-3: The experimental data of the Young’s modulus and the WVTR of parylene, 
PDMS, and the hybrid parylene/PDMS material.  A: 92µm-thick PDMS; B: 0.64µm-
thick PA-C; C: 0.34µm-thick PA-C; D: 92µm-thick PDMS coated with 0.64µm-thick 
PA-C; and E: 92µm-thick PDMS coated with 0.64µm-thick PA-C, followed by RIE to 
ethc away 0.3µm-thick surface PA-C. 
Physical property A B C D E 
Young’s modulus (MPa) 0.82 1902 1780 13.52 7.15 
WVTR (g/m2/day) 708.1 132.7 254.8 102.8 180.1 
 
Table 2-4: The theoretical results of the Young’s modulus and the WVTR of the hybrid 
parylene/PDMS material.  D: 92µm-thick PDMS coated with 0.64µm-thick PA-C; and E: 
92µm-thick PDMS coated with 0.64µm-thick PA-C, followed by RIE to ethc away 
0.3µm-thick surface PA-C. 
Physical property D E 
Young’s modulus (MPa) 13.95 7.37 
WVTR (g/m2/day) 111.8 184.7 
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The experimental data of the mechanical and the barrier properties of the hybrid 
parylene/PDMS material agree very well with the results derived from the composite 
material theory, suggesting that the parylene coatings inside PDMS pores contribute very 
little to the macroscopic mechanical or barrier properties of the hybrid parylene/PDMS 
material. 
2.3.3 Enhanced	Parylene	Penetration	into	PDMS	
2.3.3.1 Experimental Results 
A closed-loop temperature control system was built and put inside a parylene 
coater (PDS 2035CR, Specialty Coating Systems, Inc) as shown in Figure 2-8. 
 
 
Figure 2-8: Parylene deposition process with an in-situ heating setup.  Parylene N heated 
deposition process is shown as one example. 
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PDMS samples were molded in a small Petri dish and cured at 70°C for 75 
minutes.  Parylene N (PA-N), C, D (PA-D) and HT (PA-HT) (SCS products) were then 
coated on PDMS for studies.  First, each type of parylene was deposited at room 
temperature (RT) onto PDMS.  Some samples were then thermally annealed at 80°C in a 
convection oven for 8 hours, and 180°C in a vacuum oven (to prevent oxidation) for 8 
hours, respectively.  Next, each type of parylene was deposited at 80°C onto PDMS.   
 
 
(a) 
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(b) 
 
 
(c) 
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(d) 
Figure 2-9: The SIMS data of the depth profiling of parylenes N, C, D, and HT inside 
PDMS for the deposition at 80°C.  (a) The 12C profile represents the PA-N depth profile.  
(b) The 35Cl profile represents the PA-C depth profile.  (c) The 35Cl profile represents the 
PA-D depth profile.  (d) The 19F profile represents the PA-HT depth profile.  28Si profiles 
represent PDMS depth profiles. 
The parylene penetration profile into PDMS was obtained using a secondary-ion-
mass spectrometry (SIMS) (IMS 7f-GEO, CAMECA).  SIMS sputter-etches the surface 
into the depth and measures specific atomic species distribution simultaneously, then 
parylene depth profiling curves were obtained (Figure 2-9 and Figure 2-10).   
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(a) 
 
(b) 
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(c) 
 
 
(d) 
Figure 2-10: The SIMS depth profiling curves for conventional RT deposition, post-
deposition thermal annealing at 80°C and 180°C for 8 hours, and in-situ heated 
deposition at 80°C for each type of parylene.  (a) PA-N.  (b) PA-C.  (c) PA-D.  (d) PA-
HT. 
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For mechanical adhesion tests, 90µm-thick PDMS samples were spin-coated on 
silicon wafers, cured, and coated with PA-C at room temperature and 80°C, respectively.  
Then the hybrid parylene/PDMS samples were cut into 8mm-wide strips and mounted on 
a tensile test machine (DMA Q800, TA Instruments) to perform the 180° peel tests 
(Figure 2-11). 
The depth profiling curves from Figure 2-10 demonstrate that in-situ heating 
significantly increases the penetration depths for almost all parylene types.  In addition, 
post-deposition thermal annealing affects the penetration depths and the WVTR in a very 
limited way.  The adhesion strength ܴ can be evaluated using the equation [46], 
 ܴ ൌ ܨݓ ൤2 ൅
ܨ
2ܧݓݐ൨, (2-12)
where ܴ is the adhesion strength, ܨ is the peel force, ݓ is the width of the testing strips, 
and ݐ and ܧ are the thickness and the Young’s modulus of parylene layer, respectively.  
The ratio of the adhesion strengths of the hybrid parylene/PDMS samples prepared by 
deposition at 80°C to RT was found almost equal to the ratio of their peeling forces, 
which was about 1.6.  The data support the hypothesis that in-situ heated deposition is a 
very effective means to enhance the pore sealing capability of parylene coatings. 
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(a)       (b) 
 
(c) 
Figure 2-11: (a) A photo of the experimental setup.  (b) The schematic of the 180º peel 
test.  (c) The experimental data of the 180º peel tests for PDMS coated with parylene C, 
prepared by conventional RT deposition before and after post-deposition thermal 
annealing, and in-situ heated deposition at 80ºC without any post-deposition annealing. 
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2.3.3.2 Theoretical Modeling 
During the parylene deposition, the parylene monomer gas flow inside PDMS 
pores is in the free molecular flow regime, for which intermolecular collisions rarely 
happen.  The Knudsen diffusion coefficient for the free molecular flow is only dependent 
on the molecular weight, the deposition temperature and the PDMS pore diameter [47].  
A parylene deposition rate model [48] was used and became the reaction term in the mass 
balance equation.  The pore shape and geometry varied with time during the deposition.  
Then a theoretical model was proposed, in which each PDMS pore was approximated as 
an infinitely long cylindrical tube as shown in Figure 2-12. 
 
 
Figure 2-12: The schematic of parylene deposition into the PDMS pore that is modeled as 
an infinitely long circular straight tube.  The red line represents the parylene thickness 
profile inside a PDMS pore.  The PDMS pore radius is ܽ before parylene deposition, and 
݄ሺݔ, ݐሻ as a function of both depth ݔ and time ݐ after deposition.   
The Knudsen number is a dimensionless number defined as [49], 
 Kn ൌ ߣܮ, (2-13)
where ߣ  is mean free path, and ܮ  is the representative physical length scale.  For 
a Boltzmann gas, the mean free path ߣ may be readily calculated using the equation [49], 
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 ߣ ൌ ݇ܶ√2ߨ݀ଶ݌, (2-14)
where ݇ is the Boltzmann constant, ܶ is the thermodynamic temperature, ݀ is the particle 
hard shell diameter, ݌ is the total pressure. 
The deposition pressure for parylene usually ranges from 10mTorr to 100mTorr, 
under which the mean free math of the parylene monomer is of the order of 0.5mm, based 
on eqn.  (2-14).  Since PDMS is known to be a nanoporous material, its average pore size 
is expected to be of the order of 10nm.  Therefore, the mean free path ߣ of the parylene 
monomer in the vacuum deposition chamber is far larger than the PDMS pore as the 
characteristic length ܮ.  In another word, the Knudsen number Kn is on the order of 
0.5mm/10nm, which is much larger than 10, and hence the free molecular flow condition 
is satisfied. 
A parylene chemisorption deposition kinetic model was used [48], in which the 
PA-N deposition rate ܴௗሺݔ, ݐሻ depends on both the molar concentration ܿሺݔ, ݐሻ of the PA-
N monomer and the substrate temperature ܶ, 
 ܴௗሺݔ, ݐሻ ൌ
ሺ1 െ ߠሻ√ܯܴܶ
√2ߨߩ ൬1 ൅ ܣ݁ିா೏ିாೌோ் ൰
ܿሺݔ, ݐሻ, (2-15)
where ܯ is the molar mass of the PA-N monomer, ߩ is the PA-N film density, ܴ is the 
universal gas constant, ܧௗ  is the activation energy for desorption, ܧ௔  is the activation 
energy for chemisorption, ܣ is a constant, and ߠ is the coverage constant.  The values of 
the parameters used in eq. (2-15) are listed in Table 2-5 [48]. 
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Table 2-5: The values of the parameters used in eq. (2-15), the parylene chemisorption 
deposition kinetic model [48]. 
Parameter Value 
ܯ (g/mol)	 104.15 
ߩ (g/cm3) 1.11 
1 െ ߠ 1.29×10-3 
ܧௗ െ ܧ௔ (kJ/mol) 39.4 
ܣ 1.20×108 
 
The pore radius ݄ሺݔ, ݐሻ evolution with time ݐ due to parylene deposition onto the 
wall of the pore is, 
 ߲݄ሺݔ, ݐሻ߲ݐ ൌ െܴௗሺݔ, ݐሻ. (2-16)
As discussed above, the PA-N monomer gas flow inside PDMS pores is a 
Knudsen diffusion process, and hence the molar flux ݆ሺݔ, ݐሻ of the PA-N monomer is 
given by [50], 
 ݆ሺݔ, ݐሻ ൌ െ2݄ሺݔ, ݐሻ3 ඨ
8ܴܶ
ߨܯ
߲ܿሺݔ, ݐሻ
߲ݔ . (2-17)
The mass balance equation for this one-dimensional flow model is given by, 
 ߲ሾߨ݄ଶሺݔ, ݐሻܿሺݔ, ݐሻሿ߲ݐ ൌ െ
߲ሾߨ݄ଶሺݔ, ݐሻ݆ሺݔ, ݐሻሿ
߲ݔ െ 2ߨ݄ሺݔ, ݐሻܴௗሺݔ, ݐሻ
ߩ
ܯ.	 (2-18)
The boundary and initial conditions are, 
 ܿሺݔ, ݐሻ|௫ୀ଴ ൌ ݌଴ܴܶ, (2-19)
 ܿሺݔ, ݐሻ|௫→ஶ ൌ 0, (2-20)
 ܿሺݔ, ݐሻ|௧ୀ଴ ൌ 0, (2-21)
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 ݄ሺݔ, ݐሻ|௧ୀ଴ ൌ ܽ, (2-22)
where ݌଴ is the parylene deposition pressure in the vacuum chamber, 45mTorr, and ܽ is 
the PDMS pore radius before parylene deposition, which is the only fitting parameter.   
The eqns. (2-15) - (2-22) were solved numerically.  The computed deposition 
thickness profiles at different times for substrate temperatures ܶ at 20°C and 80°C are 
shown in Figure 2-13, in which the normalized cross-sectional area of parylene on the 
wall of the pore, 1 െ ሾ݄ሺݔ, ݐሻ/ܽሿଶ, is plotted against the depth ݔ. 
 
 
(a) 
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(b) 
Figure 2-13: The theoretical modeling results of the normalized depth profiles of parylene 
N deposited at (a) room temperature, and (b) 80°C into PDMS pores at different times, 
compared with the experimental normalized depth profiles.   
PA-N depth profiling curves from SIMS experiments were curve-fitted to the 
theoretical modeling results of depth profiles at time ݐ∗  such that ݄ሺ0, ݐ∗ሻ=0, which 
means that at time ݐ∗ the pore entrance was completely sealed by parylene and then the 
depth profile inside the pore wouldn’t change with time anymore.  The times at which the 
pore entrance was completely sealed for 20°C and 80°C deposition were 2.45s and 23.1s, 
respectively.  The PDMS pore diameter 2ܽ was estimated to be 6.02nm according to the 
nonlinear curve fitting.   
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2.4 Parylene Penetration into Microfluidic Channels 
Parylene, a family of poly(p-xylylene), has been widely studied [45, 51] and used 
in various industries because of their many excellent properties, such as the superior 
barrier property used to protect electronic devices against damages from moisture and 
corrosive etchants [52, 53].  PDMS is another very popular material in microdevices [54].  
Coating/caulking PDMS with parylene has been considered as an effective way to 
decrease the permeability required by various applications [41, 55, 56].  For PDMS 
microfluidics, the surface treatment can be fulfilled before or after the bonding operation.  
For the pre-bonding treatment, a further surface treatment is usually required to remove 
parylene on top of PDMS to recover the oxygen plasma bonding [42].  While thanks to 
the good conformal deposition capability, parylene C and N have been used to seal the 
inner surfaces of PDMS microfluidic devices as a post-bonding surface treatment [43, 55, 
56].  M.  Akhtar et.  al.  have recently reported that coating parylene AF4 (parylene HT) 
into PDMS channels will improve its on-chip droplet storage life [57].  However, a 
comprehensive understanding of the parylene penetration inside the microchannel is still 
lacking and the important factors for this penetration process are largely unknown.   
This section presents the establishment of theoretical modeling and the 
experimental study of the effects of dimer type, loaded dimer mass, substrate temperature, 
and channel size on the penetration process.  The penetration length, which is a measure 
of how far parylene can be deposited into the microfluidic channel from the inlet, was 
used to evaluate the parylene penetration performance. 
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2.4.1 Theoretical	Modeling	
The deposition pressure for parylene typically ranges from 10mTorr to 100mTorr, 
under which the mean free math of the parylene monomer is of the order of 0.5mm.  
Since the typical characteristic size of a microfluidic channel is expected to be of the 
order of tens of micrometers, the mean free path ߣ of the parylene monomer gas in the 
vacuum deposition chamber is far larger than the characteristic size (i.e., the hydraulic 
diameter ܦ௛) of the microfluidic channel.  In another word, the Knudsen number Kn is 
much larger than 1, and hence the free molecular flow condition is satisfied, for which 
intermolecular collisions rarely happen.  The Knudsen diffusion coefficient for the free 
molecular flow is only dependent on the molecular weight, the deposition temperature 
and the channel characteristic size.  The deposition rate as a function of deposition 
pressure for parylene N was measured at room temperature, and then became the reaction 
term in the mass balance equation.  The deposition thickness was small compared with 
the channel height ݄  and width ݓ , therefore the channel cross-sectional shape was 
assumed invariant with time during the deposition.  Finally, a theoretical kinetic model of 
parylene deposition into the microfluidic channel was proposed.  The schematic drawing 
of the geometry of the rectangular micro-channel was shown in Figure 2-14.   
 
 
Figure 2-14: The illustration of the microfluidic channel.  The channel width ݓ, height ݄ 
and half-length ܮ/2 are indicated. 
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The parylene N deposition rate ܴௗሺݔሻ at room temperature only depends on the 
molar concentration ܿሺݔሻ of the parylene N monomer [58], which varies with the distance 
ݔ from the channel inlet, 
 ܴௗሺݔሻ ൌ ݇ ቈܿሺݔሻܴܶ݌଴ ቉
௡
, (2-23)
where ܴ  is the universal gas constant, ܶ  is the room temperature, 293.15K, ݌଴  is the 
deposition pressure in the vacuum deposition chamber, 45mTorr in our experiment, ݇ is 
the rate constant, and ݊  is the reaction order.  First, ݇  and ݊  were estimated to be 
0.675m/hour and 0.8225, respectively, based on our own measurement data, 
As discussed above, the parylene N monomer gas flow inside the channel is a 
Knudsen diffusion process, hence the molar flux ݆ሺݔሻ of the parylene N monomer is 
given by, 
 ݆ሺݔሻ ൌ െܦ௛3 ඨ
8ܴܶ
ߨܯ
݀ܿሺݔሻ
݀ݔ , (2-24)
where ܯ  is the molar mass of the parylene N monomer, 104.15g/mol, and ܦ௛  is the 
hydraulic diameter of the channel defined as, 
 ܦ௛ ൌ 2ݓ݄ݓ ൅ ݄, (2-25)
where ݓ and ݄ are the channel width and height, respectively. 
The mass balance equation for the one-dimensional flow is given by, 
 ݀ሾݓ݄݆ሺݔሻሿ݀ݔ ൌ െ2ሺݓ ൅ ݄ሻܴௗሺݔሻ
ߩ
ܯ, (2-26)
where ߩ is the parylene N film density, 1.11g/cm3. 
The boundary conditions are, 
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 ܿሺݔሻ|௫ୀ଴ ൌ ݌଴ܴܶ, (2-27)
 
݀ܿ
݀ݔฬ௫ୀ௅/ଶ ൌ 0, (2-28)
where ܮ is the total channel length, 10.5cm in our study.   
Here, due to the symmetry of the channel geometry with both ends opened, we 
only needed to model one half of the channel, which was opened at one end, but confined 
at the other end. 
The model equations eqns. (2-23) - (2-28) were solved numerically using a finite 
element analysis software (COMSOLTM). 
2.4.2 Experimental	Procedure	
PDMS microfluidic channels with different sizes (120m, 240 m, and 480 m in 
width; 18m, 30m, 60m, and 120m in height) were prepared following the standard 
soft lithography process.  Briefly, pre-polymer was prepared by mixing the base and the 
curing agent (Sylgard® 184, Dow Corning Corp.) with a ratio of 10:1 by weight.  After 
degassing in vacuum for 15min, the pre-polymer was poured onto the silicon master and 
cured at 100°C for one hour.  Inlets and outlets were obtained by punching through holes.  
The so-prepared PDMS microfluidic channels were directly attached to A174-treated 
silicon wafers to form close microchannels.  Parylene depositions were then performed in 
PDS 2035CR parylene coater (SCS Inc.) with parylene C/N/HT dimers.  A custom-made 
hot plate was used to control the substrate temperatures during deposition.  After the 
deposition, the PDMS microchannel was peeled off and the parylene film left on the 
silicon wafer was measured by a profilometer (P15, KLA-Tencor).   
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2.4.3 Results	and	Discussion	
A typical distribution of pressure and film thickness inside a microchannel 
calculated based on eqns. (2-23) - (2-28) is showed in Figure 2-15.   
 
 
Figure 2-15: The variations of pressure and film thickness along the microchannels 
calculated based on the time-independent free molecular flow model.  Deposition is a 
parylene N deposition at room temperature, and the channel is 120m deep and 480m 
wide. 
Figure 2-16 shows the parylene thickness distribution inside the microchannels 
for different dimers.  The dimer weight was 11.13g, 20.41g, and 30.73g for parylene C, N 
and HT, respectively.  The deposition pressures were 7mTorr, 45mTorr, and 50mTorr for 
parylene C, N, and HT, respectively.  Substrates were kept at room temperature in all 
depositions.  The penetration length is a measure of how far parylene can go inside the 
channel, and defined as the distance between the inlet and the point at which the parylene 
thickness on the wall of the channel drops to a half of that at the inlet.  The results 
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showed that the penetration length of parylene HT was the longest, likely because 
parylene HT has the lowest sticking coefficient among all parylene types.  On the other 
hand, lighter molecules have larger free molecular diffusivities and thereby likely 
penetrate further than heavier ones, which may explain that the penetration length of 
parylene N is bigger than that of parylene C.   
 
 
Figure 2-16: The variation of parylene deposition thickness inside microchannels for 
different dimer types.  The right three figures show the photos of the deposited films on 
the silicon wafers.  The scale bar is 1mm.   
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Figure 2-17: The variation of parylene deposition thickness inside microchannels for 
different loading weight of parylene N dimer.  The inset figure is the numerical 
calculation based on the present theoretical model.  The right three figures show the 
photos of the deposited films on the silicon wafers.  The scale bar is 1mm.   
Theoretically, parylene N is a more desired choice for the microchannel’s inner 
surface coating so the deposition performance of parylene N inside the microchannel for 
different dimer loading weight was studied in Figure 2-17.  The deposition pressure was 
45mTorr.  Substrates were kept at room temperature in all depositions.  It showed that 
more loading of dimers resulted in a longer penetration length, which was largely 
attributed to the longer deposition time.  The experimental measurement gave a shorter 
penetration length compared to that obtained based on the theoretical model which has 
the best predictive power for silicon channels, suggesting that the kinetics of deposition 
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into a channel made of PDMS, a nanoporous material, will be different from that for a 
silicon channel (Figure 2-17).   
To study deposition temperature effects, in-situ heating the substrate was applied 
during the parylene N deposition.  The deposition pressure was 45mTorr, and the dimer 
weight was 41.18g.  As shown in Figure 2-18, the penetration lengths were nearly the 
same for depositions at substrate temperatures of 20°C, 60°C, and 80°C, while the film 
thicknesses inside channels dramatically decreased with increasing substrate temperatures.  
This result supported the fact that the dominant process is the mass transport in the free 
molecular flow regime, instead of the deposition kinetics.   
 
 
Figure 2-18:  The variation of parylene deposition thickness inside microchannels for 
different substrate temperatures.  The right three figures show the photos of the deposited 
films on the silicon wafers.  The scale bar is 1mm.   
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Beside the diffusion inside the microchannel, parylene monomers also penetrated 
into the nanoporous PDMS substrate, which requires further experimental and theoretical 
study.  Penetration into PDMS substrate may also affect the reaction boundary condition 
considerably and thereby lead to the present experimental observation.   
The results of effects of the channel dimensions on parylene N deposition profiles 
inside the microchannels were shown in Figure 2-19.  The deposition pressure was 
45mTorr, the substrate temperature was 60°C, and the dimer weight was 40.32g.  It 
shows that channels with smaller characteristic heights have longer deposition lengths, 
indicating a porous surface effect of the PDMS.   
 
 
Figure 2-19:  The variation of parylene deposition thickness inside microchannels for 
different geometric sizes of the channels.  The right four figures show the photos of the 
deposited films on the silicon wafers.  The scale bar is 1mm.   
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Rhodamine (1mmol/L in deionized water) diffusion tests were carried out to 
examine the inner surface protection performances.  As shown in Figure 2-20, parylene N 
deposition at a higher temperature has the best inner surface sealing performance. 
 
 
Figure 2-20: Rhodamine diffusion tests in microchannels made of pure PDMS (upper), 
PDMS coated with parylene HT at room temperature (middle), and PDMS coated with 
parylene HT at 60°C (bottom). 
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2.5 Application of Parylene and Silicone in a Capillary Pressure-Driven 
Viscometer 
2.5.1 Overview	
This chapter presents the first experimental work on the viscosity measurement of 
adult zebrafish whole blood using a capillary pressure-driven microfluidic viscometer.  
After the device calibration with water, the viscosity measurement of human whole blood 
was performed, and the results were in good agreement with the published data, 
demonstrating the reliability of the device.  The power law, the simplified Cross, the 
Cross, and the Carreau-Yasuda rheological models were used to model the non-
Newtonian behaviors of the human and zebrafish whole blood.  Theoretical modeling and 
numerical algorithms were applied to determine the blood viscosity over a wide range of 
shear rates.  The proposed approach is uniquely applicable for small sample volume 
(down to 1µL or less), and short measurement time (<3min).  A wide range of shear rates 
was produced in a single test. 
Hemodynamics has a significant impact on cardiac development [59], and 
rheological properties of blood play significant roles in the progression of coronary and 
peripheral vascular diseases [60].  Hemodynamic factors such as flow separation, flow 
recirculation, and low and oscillatory wall shear stress are recognized as playing 
important roles in the localization and development of vascular diseases.  Currently, 
assessment of mammalian mechano-transduction underlying intracardiac morphogenesis 
is hampered by the complexity of surrounding internal organ systems, coupled with a 
prolonged duration of development.  Fluid shear stress generated by circulating blood is 
intimately linked with cardiac morphogenesis.  The shear forces impart mechano-signals 
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to up-regulate developmental genes, with implications in endocardial cushion and 
atrioventricular (AV) valvular formation [59, 61, 62].  The exposure of the endocardium 
to shear forces also transmits mechano-signals to the myocardium [63, 64], with 
implications in cardiac looping and trabeculation [63, 65].   
 
 
Figure 2-21: The comparison between normal heart and heart with left ventricular 
noncompaction. 
Clinically, developmental defects in the AV valve result in flow regurgitation, 
while the absence of an endocardial cushion results in AV septal defects in patients with 
congenital heart disease (CHD).  For example, left ventricular non-compaction 
cardiomyopathy (LVNC) is a congenital cardiomyopathy, characterized by deep 
trabeculations (finger-like projections) in the muscle wall of the left ventricle (Figure 
2-21) [66].  The heart muscle abnormalities result from the failure of myocardial 
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development during embryogenesis.  Symptoms of the disease are associated with a 
reduced pumping performance of the heart, including breathlessness, fatigue, palpitations, 
swelling, dizziness, and fainting episodes.  Occasionally the disease can cause heart 
failure, stroke (due to blood clots forming in the trabeculations then travelling to the brain) 
or sudden death.  Thus, hemodynamic analyses and interpretation of cardiac 
morphological changes are both clinically and developmentally significant. 
The zebrafish (Danio rerio) is genetically tractable and emerging as a more and 
more popular animal model for investigating cardiac morphogenesis.  Its transparency 
and short developmental time enable imaging and high throughput analysis of various 
developmental stages.  Computational fluid dynamics (CFD) has been applied to simulate 
endocardial blood flow for developmental embryonic zebrafish model to establish 
quantitative analysis underlying morphological changes during development, to facilitate 
clinical decision-making, and to study the progression of cardiovascular diseases [67].  
Therefore, mathematical and numerical simulations of blood flow in the vascular system 
can ultimately contribute to improved clinical diagnosis and therapeutic planning. 
However, meaningful hemodynamic simulations require constitutive models that 
can accurately model the rheological response of blood over a range of physiological 
flow conditions.  The rheological properties of zebrafish whole blood remain unclear, and 
only “intelligent” estimate of whole blood viscosity of zebrafish was used [68].  The 
composition of zebrafish whole blood was assumed to be similar to that for human, and 
viscosity was estimated from the relative viscosity and particle volume fraction using 
literature data [61, 68], and the density of blood was assumed to be similar to that for 
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human (1.06g/cm2).  Therefore, we will present the viscosity measurement of zebrafish 
whole blood for the first time. 
On the other hand, although conventional viscometers such as cone and plate 
viscometers allow detailed rheological analysis, they demand relatively large sample 
volume (0.5-3mL) and long measurement time inherently [69, 70].  Hence, to prevent 
coagulation when testing the blood, they generally require the use of anticoagulants, 
which can alter the blood viscosity [71] and lead to measurement inaccuracies.  
Alternatively, scanning capillary-tube viscometer, mass-detecting capillary viscometer, 
and pressure-scanning capillary viscometer [72-74] have been proposed to provide very 
fast measurement (<3min) and then require no anti-coagulants.  However, one 
disadvantage is that they require a relatively large amount of blood (~3mL), and therefore 
are not suitable for zebrafish blood because only a few microliters of blood can be 
harvested from a zebrafish [75].  In addition, a fast MEMS oscillating micro-mechanical 
viscometer [76] has been designed to use small sample volume, however, the viscosity 
measurement can only be obtained at a specific shear rate at one time, making the process 
laborious and time consuming, especially for blood as a non-Newtonian fluid, for which 
the viscosity data over a wide range of shear rates are desired.  For example, the shear 
rates ranging from 43s-1 to 1600s-1 are typically found in human blood vessels [77] (Table 
2-6). 
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Table 2-6: Physiological flow parameters for the human circulation [77]. 
Vessel Diameter (mm) Mean Wall Shear Rate (1/s) 
Ascending Aorta 23 – 43.5 45 – 300 
Femoral Artery 5 300 
Common Carotid 5.9 250 
Carotid Sinus 5.2 240 
External Carotid 3.8 330 
Capillaries 0.005 – 0.01 400 – 1600 
Large Veins 5 – 10 120 – 320 
Vena Cava 20 44 – 64 
Thoracic Inferior 20 43 – 64 
 
In this chapter, a capillary pressure-driven viscometer was designed to overcome 
the aforementioned limitations by demanding small amount of samples (down to 1µL or 
less) and producing a wide range of shear rates in a single run for continuous viscosity 
measurements that simulated the physiological flow environment.  This device also 
featured short measurement time (<3min), and hence required no addition of anti-
coagulants that could alter the blood viscosity.  The device was made from PDMS, a 
widely studied structural material [51] for making microdevices [53, 54], as well as glass.  
This capillary viscometer is disposable, hence avoiding cleaning and contamination.  The 
viscosity measurement of adult zebrafish whole blood was produced for the first time. 
There is also increasing clinical interest in the viscosity measurement of human 
whole blood as an aid to the diagnosis of cardiovascular conditions [78], such as mapping 
hyperlipidemic and hypertensive states.  Since this viscometer is fast and cheap, it could 
even be used in hospitals for daily routine use, in monitoring certain cardiovascular 
diseases such as atherosclerosis for patients. 
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2.5.2 Theoretical	Modeling	
 
(a) 
 
(b) 
Figure 2-22: The composition of human whole blood.  (a) The percentages of various 
components revealed by centrifuging blood in a hematocrit tube.  (b) The various types of 
blood cells.  RBCs make up 99% of the formed cellular elements.  White blood cells and 
platelets make up the remaining 1%. 
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Whole blood is a concentrated suspension of formed cellular elements that 
includes red blood cells (RBCs) or erythrocytes, white blood cells (WBCs) or leukocytes, 
and platelets or thrombocytes.  Plasma consists primarily of water (approximately 90–
92% by weight) in which inorganic and organic substances (approximately 1–2%), 
various proteins (mostly albumin, globulins, and fibrinogen) as well as many other 
components are dissolved.  The RBCs represent approximately 45% by volume of the 
normal human whole blood, the remaining cellular elements represent less than 1%, and 
the plasma represents about 55% (Figure 2-22). 
The volume concentration of RBCs in whole blood is called the hematocrit.  It is 
measured by centrifuging blood in a hematocrit tube and measuring the volume occupied 
by the packed cells in the bottom of the tube (Figure 2-22).  Normal hematocrit levels for 
women and men are about 40% and 45% on average, respectively.  The typical size of a 
RBC is shown in Figure 2-23. 
 
     (a)           (b) 
Figure 2-23: (a) A scanning electron microscope image of a red blood cell. (b) The 
schematic of a RBC profile with average geometric parameters from 14 healthy subjects. 
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The complex constitution of blood renders it a non-Newtonian fluid, especially a 
shear-thinning or pseudoplastic fluid, which has a lower apparent viscosity at higher 
shear strain rates (Figure 2-24).  At low shear rates (low flow speeds), RBCs aggregate, 
increasing the resistance to flow (viscosity) of whole blood.  In the presence of fibrinogen 
and large globulins (proteins found in plasma) RBCs have the ability to form a primary 
aggregate structure of rod-shaped stacks of individual cells called rouleaux (Figure 2-25).  
As flow speeds increase, RBC aggregates dissociate and line up in a more streamlined 
manner.  As flow speeds increase further, RBCs begin to deform and assume an 
elongated shape that further decreases the resistance to flow.   
 
Figure 2-24: Whole blood behaves as a non-Newtonian fluid [79].  Whereas plasma has a 
constant viscosity regardless of the shear rate, the viscosity of whole blood depends on 
the shear rate of flow.  This behavior is largely due to RBCs. 
71 
 
 
(a)    (b)    (c) 
Figure 2-25: The view of RBCs from normal human blood [77].  In (a), they are seen 
forming rouleaux (interference microscopy).  In (b) and (c), they have been fixed with 
glutaraldehyde while sheared in a viscometer under a shear stress of (b) 10Pa and (c) 
300Pa. 
2.5.2.1 Analytical Derivation 
 
 
Figure 2-26: The side view of the microfluidic channel as the capillary pressure-driven 
viscometer.  The liquid column length ܮሺݐሻ, the velocity distribution ݑሺݕ, ݐሻ, the mean 
liquid advancing velocity ݒሺݐሻ , the channel height ݄ , and the contact angle ߠ  are 
indicated.  The dotted arrow indicates the flow direction. 
A common empirical non-Newtonian viscosity model is the two-parameter power 
law model, 
 ߟ ൌ ݉ߛሶ ௡ିଵ, (2-29)
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where ߟ is the viscosity, ߛሶ 	is the shear rate, ݊ is the power law exponent (݊ ൏ 1 for shear-
thinning fluids such as blood, ݊ ൌ 1 for Newtonian fluids such as water, and ݊ ൐ 1 for 
shear-thickening fluids), and ݉ is a constant. 
For the plane Poiseuille flow inside a thin rectangular microchannel, the velocity 
field lies in the ݔ direction and is a function of ݕ alone (Figure 2-26), and the pressure 
gradient also lies in the ݔ direction, 
 0 ൌ െ݀݌݀ݔ ൅
߲ሺߟߛሶሻ
߲ݕ , (2-30)
 ߛሶ ൌ ߲ݑሺݕ, ݐሻ߲ݕ , (2-31)
 െ݀݌݀ݔ ൌ
݌௖௔௣௜௟௟௔௥௬
ܮሺݐሻ , (2-32)
where	ݑሺݕ, ݐሻ is the flow velocity in the ݔ direction at constant ݕ,	݀݌/݀ݔ is the pressure 
gradient in the ݔ direction, ܮሺݐሻ is the liquid column length inside the channel at time ݐ, 
and	݌௖௔௣௜௟௟௔௥௬ is the capillary pressure given by the Young-Laplace equation, 
 ݌௖௔௣௜௟௟௔௥௬ ൌ 2ߪcosߠ ൬1݄ ൅
1
ݓ൰. (2-33)
Here, ߪ is the surface tension of the liquid, ߠ is the contact angle, and ݄ and	ݓ are 
the channel height and width, respectively.   
The velocity distribution ݑሺݕ, ݐሻ  is averaged over ݕ  to yield the mean liquid 
advancing velocity ݒሺݐሻ, 
 ݒሺݐሻ ൌ 1݄න ݑሺݕ, ݐሻ݀ݕ
௛/ଶ
ି௛/ଶ
. (2-34)
For the power law model, an analytical relation between ܮሺݐሻ and ݒሺݐሻ could be 
derived [70],  
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1
ܮሺݐሻ ൌ ܥݒሺݐሻ
௡, ܽ݊݀ ܥ ൌ 2݄݉݌௖௔௣௜௟௟௔௥௬ ൬
ܵ
2݄
2݊ ൅ 1
3݊ ൰
௡
,	 (2-35)
where ܵ is a constant specific to the channel geometry (e.g., ܵ ൌ 12 for a rectangular 
channel with ݄ ≪ ݓ [70]).  Integrating eqn. (2-35), we obtain ܮሺݐሻ as a function of time ݐ, 
 ܮሺݐሻ ൌ ൬݊ ൅ 1ܥଵ/௡݊ ݐ൰
௡/ሺ௡ାଵሻ
. (2-36)
The wall shear rate ߛሶ௪ and the viscosity at the wall ߟ௪ are given by  
 ߛሶ௪ ൌ ܵݒሺݐሻ2݄
2݊ ൅ 1
3݊ , (2-37)
 ߟ௪ ൌ ݄
ଶ
ܵ
3݊
2݊ ൅ 1
݌௖௔௣௜௟௟௔௥௬
ݒሺݐሻܮሺݐሻ . (2-38)
The liquid column length ܮሺݐሻ was monitored under a microscope with a CCD 
camera and measured with a ruler microfabricated together with the channel.  The mean 
liquid advancing velocity ݒሺݐሻ was calculated based on the incremental column length 
increase ∆ܮ  over the short time interval ∆ݐ  (i.e., ݒሺݐሻ ൌ ∆ܮ/∆ݐ ).  The power law 
exponent ݊  was found from the log-log plot of 1/ܮሺݐሻ  versus ݒሺݐሻ .  The capillary 
pressure ݌௖௔௣௜௟௟௔௥௬  was given by eqn. (2-33) in which ߪ  is 0.058N/m for blood and 
0.073N/m for water at 20°C.  The viscosities at different shear rates were obtained by 
calculating eqns. (2-37) and (2-38).  The constant ܵ  was determined by using a 
Newtonian calibration liquid of known viscosity, which was water in our study.  The 
water viscosity at 20°C is 1.002cP, and ݊ is 1 for water. 
2.5.2.2 Numerical Algorithm and Simulation 
More sophisticated non-Newtonian constitutive viscosity models are generally 
written as, 
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 ߟ ൌ ߟஶ ൅ ሺߟ଴ െ ߟஶሻ݂ሺߛሶሻ, (2-39)
where ݂ሺߛሶሻ is called the viscosity function, and both ߟ଴ and ߟஶ are constants.  A few 
examples of ݂ሺߛሶሻ with corresponding material constants are, 
 ݂ሺߛሶሻ ൌ
ە
ۖۖ
۔
ۖۖ
ۓ 11 ൅ ߣߛሶ , for the simplified Cross model	
1
1 ൅ ሺߣߛሶሻଵି௡ ,										for	the	Cross	model
		 1
ሾ1 ൅ ሺߣߛሶሻ௔ሿଵି௡௔
,							for	the	Carreau－Yasusda	model
. 
 
(2-40)
The Carreau–Yasuda model contains simplified Cross and Cross models as 
special cases.  For small values of ሺߣߛሶሻ௔ (the zero-shear-rate region), the viscosity tends 
to a plateau of constant ߟ଴.  In the limit of large ሺߣߛሶ ሻ௔ (the power law region), this model 
tends to a power-law-type model with non-zero ߟஶ.  For this reason, ݊ is referred to as 
the “power law exponent”.  In the special case of the Cross model, ܽ ൌ 1 െ ݊, while in 
the simplified Cross model, ܽ is set equal to 1 and ݊ is set to zero.  For ߛሶ → 0, ߟ → ߟ଴, 
and for ߛሶ → ∞, ߟ → ߟஶ, hence ߟ଴ and ߟஶ are the upper and lower limiting values of the 
fluid viscosity, respectively.  And ߣ is the time constant, that is, inverse of the shear rate 
at which the fluid changes from Newtonian to power law behavior.  Let ࢼ denote the 
parameter column vector for each of the three generalized viscosity models, that is, 
ࢼ ൌ ሺߟ଴, ߟஶ, ߣሻ୘ for the simplified Cross model, ࢼ ൌ ሺߟ଴, ߟஶ, ߣ, ݊ሻ୘ for the Cross model, 
and ࢼ ൌ ሺߟ଴, ߟஶ, ߣ, ݊, ܽሻ୘  for the Carreau-Yasuda model.  Then the three constitutive 
models can be expressed as ߟ ൌ ߟሺߛሶ ; ࢼሻ. 
Unfortunately, there do not exist analytical solutions to the flow equation eqn. 
(2-30) for the three generalized models, hence, numerical algorithms and simulation tools 
must be applied to estimate the parameter vector ࢼ for each model.   
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Our goal is to optimize the set of parameters ࢼ in each viscosity model such that 
the error function ܧሺࢼሻ is minimized, 
 ܧሺࢼሻ ൌ෍ሾܮ௜ െ ܮሺݐ௜; ࢼሻሿଶ
ே
௜ୀଵ
, (2-41)
where ܰ is the total number of data points,  ܮ௜ is the measured liquid column length at 
time ݐ௜, and ܮሺݐ௜; ࢼሻ is the theoretical liquid column length at time ݐ௜.  Here ܮሺݐ௜; ࢼሻ is 
obtained by solving the three-dimensional Navier-Stokes equation,  
 ߩܝ ∙ ׏ܝ ൌ െ׏݌ ൅ 2׏ ∙ ሾߟሺߛሶ ; ࢼሻDሿ, (2-42)
where ߩ is the density of the liquid, ܝ is the velocity field vector, ׏݌ is the pressure 
gradient, D ൌ ሾ׏ܝ൅ሺ׏ܝሻ୘ሿ/2 is the rate of deformation tensor.  Here, the shear rate ߛሶ  is 
defined as ඥ2trሺDଶሻ, which is a scalar invariant that has meaning in any flow field, and 
reduces to eqn. (2-31) for the plane Poiseuille flow. 
The eqn. (2-42) was solved by COMSOL MultiphysicsTM to yield the velocity 
field ܝ at time ݐ௜, noting that the pressure gradient in the flow direction at time ݐ௜ was 
݌௖௔௣௜௟௟௔௥௬/ܮሺݐ௜; ࢼሻ.  Then ݒሺݐ௜ሻ was computed by averaging the velocity component in 
the flow direction over the cross-sectional surface of the channel.  To the first-order 
approximation, the theoretical liquid column length at time ݐ௜ ൅ ∆ݐ was, 
 ܮሺݐ௜ ൅ ∆ݐ ; ࢼሻ ൌ ܮሺݐ௜; ࢼሻ ൅ ݒሺݐ௜ሻ∆ݐ, (2-43)
where ∆ݐ is a sufficiently small time interval.  Thus under the new pressure gradient 
݌௖௔௣௜௟௟௔௥௬/ܮሺݐ௜ ൅ ∆ݐ; ࢼሻ, the flow equation was solved again to yield ݒሺݐ௜ ൅ ∆ݐሻ.  Finally, 
ܮሺݐ௜; ࢼሻ for ݅ ൌ 1,2,⋯ܰ was able to be obtained numerically for any arbitrarily chosen ࢼ.  
Then the parameter vector ࢼ for each model was optimized by the Levenberg-Marquardt 
algorithm [80], a popular parameter estimation algorithm to solve the nonlinear least 
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squares curve-fitting problems such as eqn. (2-41).  To start a minimization, an initial 
guess is provided to the parameter vector ࢼ.  In each iteration step, ࢼ is replaced by a 
new estimate, ࢼ ൅ ࢾ, and ࢾ is determined by the equation, 
 ሺJ୘J ൅ ߣdiagሺJ୘Jሻሻࢾ ൌ J୘ሺࡸ െ ܮሺ࢚; ࢼሻሻ, (2-44)
where ߣ  is the damping factor, ࡸ  and ܮሺ࢚; ࢼሻ  are vectors with ith component 
ܮ௜  and ܮሺݐ௜; ࢼሻ , respectively, and J  is the Jacobian matrix whose ith row equals ܬ௜ ൌ
ሾ߲ܮሺݐ௜; ࢼሻ/߲ࢼሿ୘.  This iterative process is continued until the desired tolerance is reached.  
Finally, the optimized parameter set ࢼ is substituted into each corresponding viscosity 
model written as ߟ ൌ ߟሺߛሶ ; ࢼሻ to yield the non-Newtonian behavior of the testing liquid, 
i.e., ߟ ൌ ߟሺߛሶሻ , and then we compare the results from choosing different rheological 
viscosity models. 
2.5.3 Device	Design	and	Fabrication	
A high-aspect-ratio and meandering microfluidic channel was preferred for the 
device geometrical configuration (Figure 2-27).   
The device dimensions were such that ݓ/݄ ൌ 4 (e.g., when ݄=30µm, ݓ=120µm; 
when ݄=60µm, ݓ=240µm), the length of one straight segment was 1cm, the separation 
between adjacent straight segments was 0.5mm, and the total length of the meandering 
rectangular microchannel was 10.5cm. 
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(a) 
 
 
(b) 
Figure 2-27: The meandering microfluidic channel design.  (a) Top view.  The liquid 
column length L and the channel width w are denoted.  The total length of the 
microfluidic channel is 10.5cm.  (b) Isometric view.  The channel width w and height h 
are denoted.  The fluid flows in the x direction. 
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(a) 
 
 
(b) 
Figure 2-28: (a) The device fabrication process involves two main steps: PDMS molding 
and PDMS-glass oxygen plasma bonding.  (b) A photo of a finished device. 
The device fabrication process is schematically shown in Figure 2-28.  A silicon 
master was fabricated using photolithography and deep reactive ion etching (DRIE), and 
coated with 10µm Parylene C film to facilitate the future release of PDMS.  Then, PDMS 
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(Sylgard 184, Dow Corning) was cast into the silicon master by mixing base and curing 
agent at a 10:1 ratio by weight, degassing under vacuum, and curing at 100°C for 4 hours.  
The surfaces of the PDMS and a clean soda-lime glass wafer were activated by oxygen 
plasma (PEII-A plasma etcher, Technics) for 10 seconds at a RF power of 45W and a 
pressure of 300mTorr, and bonded to each other immediately to produce rectangular 
microfluidic channels.  Another 10 seconds of plasma treatment was also applied to the 
inlet of the channel to facilitate the water/blood to enter it.  The viscosity measurements 
must be performed within 15 minutes of bonding PDMS to glass, when the microfluidic 
channels are very hydrophilic and the contact angles for both water and blood remain 
smaller than 15° (taking ߠ=10° in the calculation of ݌௖௔௣௜௟௟௔௥௬).  The liquid column length 
ܮ was measured with a ruler microfabricated together with the channel (Figure 2-28). 
2.5.4 Characterization	Results	and	Discussions	
As the calibration of the channel, the viscosity measurement of water at 20°C 
(Figure 2-29) was performed in a channel with ݄=60µm and ݓ=240µm such that the 
geometry-specific constant ܵ was determined to be 14.4 based on the fact that the water 
viscosity at 20°C is 1.002cP, and ݊ is 1 for water.  The measured parameters ݉ and ݊ in 
the power law model for water is listed in Table 2-7. 
To obtain a few microliters of human whole blood sample, a finger-stick device 
(ACCU-CHEK® Multiclix lancing device) was used to take blood samples from the 
fingertip of a 27-year-old male donor (Figure 2-30).  Then we used a 1.0–10.0µL 
micropipette to transfer about 3µL of blood from the fingertip to the inlet of the 
microfluidic channel. 
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(a)      (b) 
 
 (c)      (d) 
Figure 2-29: The viscosity measurement of water in a channel with ݄ =60µm and 
ݓ=240µm at 20°C.  (a) The water column length ܮ vs. time ݐ.  (b) The mean water 
advancing velocity ݒ vs. time ݐ.  (c) The log-log plot of 1/ܮ versus ݒ.  The slope gives 
the power law exponent ݊=1.05.  (d) The viscosity of water vs. the shear rate at 20°C, 
using ܵ=14.4 to let the measured water viscosity match with 1.002cP at 20°C. 
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Table 2-7: The measured parameters ݉ and ݊ in the power law model for water at 20°C 
using a channel with ݄=60µm and ݓ=240µm 
Parameter set ࢼ For waterMeasured Published
݉ (cP/s1-n) 1.053 1.002 
݊ 1.05 1 
 
 
Figure 2-30: A finger-stick device is used to obtain a few microliters of human whole 
blood sample. 
The videos of the human whole blood motion inside the channels were recorded 
at 30fps.  Then we used an image-converting freeware to exact frames from video files 
and converted them directly into image format.  The snapshots of human whole blood 
columns inside a meandering channel with ݄=60µm and ݓ=240µm at three different 
times are shown in Figure 2-31.  The distance between the inlet and the point 
corresponding to the zero position on the microfabricated ruler is 0.5mm.   
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(a) 
 
(b) 
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(c) 
Figure 2-31: The snapshots of human whole blood columns inside a meandering channel 
with ݄=60µm and ݓ=240µm at (a) ݐ=0.14s, (b) ݐ=12.02s, and (c) ݐ=73.32s. 
After the device calibration with water, the viscosity measurement of human 
whole blood in a channel with h=60µm and w=240µm at 20°C was then performed.  The 
measurement data are shown in Figure 2-32. 
The estimated values of the parameters in the Carreau-Yasuda model for human 
whole blood based on the Levenberg-Marquardt algorithm are summarized in Table 2-8. 
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(a)      (b) 
 
 
(c)      (d) 
Figure 2-32: The viscosity measurement of human whole blood in a channel with 
݄=60µm and ݓ=240µm at 20°C.  (a) The blood column length ܮ vs. time ݐ.  (b) The 
mean blood advancing velocity ݒ vs. time ݐ.  (c) The log-log plot of 1/ܮ versus ݒ, giving 
݊=0.745.  (d) The blood viscosity vs. shear rate using the power law model.  Shear rates 
range from 69.4s-1 to 6642.0s-1. 
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Table 2-8: The values of the fitting parameters in the Carreau-Yasuda model for non-
Newtonian human whole blood at 20°C based on the viscosity measurement in a 
microfluidic channel with h=60µm and w=240µm. 
Model ࢌሺࢽሶ ሻ Parameter Values for human whole blood 
Carreau-Yasuda 
1
ሾ1 ൅ ሺߣߛሶሻ௔ሿሺଵି௡ሻ ௔⁄
ߟ଴ (cP) 65.7 
ߟஶ (cP) 1.31 
ߣ (s) 10.396 
݊ 0.6935 
ܽ 1.76 
 
The measurement data for the human whole blood viscosity by using the proposed 
viscometer device with ݄ =60µm and ݓ =240µm are in good accordance with the 
published data [81] (Table 2-9).   
Table 2-9: The measurement data for the viscosities of human whole blood at room 
temperature at different shear rates based on the power law and Carreau-Yasuda non-
Newtonian viscosity models, and the published data [81]. 
Shear rate (1/s) 
Measured viscosity (cP) Published 
viscosity data (cP) 
at 22°C [81] Power law Carreau-Yasuda 
71.89 10.4±0.1 9.78 ~9.3 
105.93 8.0±0.1 8.83 ~8.6 
124.07 7.6±0.2 8.48 ~8.3 
154.82 6.6±0.1 8.01 ~8.1 
182.97 6.2±0.1 7.67 ~7.8 
215.65 6.0±0.2 7.36 ~7.5 
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The snapshots of the liquids (i.e., water, human whole blood and adult zebrafish 
whole blood) inside the meandering channels with ݄=30µm and ݓ=120µm are shown in 
Figure 2-33.  The distance between the inlet and the point corresponding to the zero 
position on the microfabricated ruler is 0.5mm. 
 
 
                    (a)                            (b)                                       (c) 
Figure 2-33: The snapshots of the liquid columns inside the channels with ݄=30µm and 
ݓ=120µm.  ܮ is measured by the ruler microfabricated together with the channel.  (a) 
Water.  (b) Human whole blood.  (c) Adult zebrafish whole blood.   
As the calibration of the channel, the viscosity measurement of water (Figure 2-34) 
was performed in a channel with ݄=30µm and ݓ=120µm such that the geometry-specific 
constant ܵ was determined to be 13.6.  To obtain about 3µL of unadulterated human 
whole blood samples, a finger-stick device was used to take blood samples from the 
fingertips of a 27-year-old male donor.  After the device calibration water, the viscosity 
measurement of human whole blood was produced and shown in Figure 2-35. 
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                                    (a)                            (b)     
 
 
                                     (c)                                       (d) 
Figure 2-34: The viscosity measurement of water in a channel with ݄ =30µm and 
ݓ=120µm at 20°C.  (a) The water column length ܮ vs. time ݐ.  (b) The mean water 
advancing velocity ݒ vs. time ݐ.  (c) The log-log plot of 1/ܮ versus ݒ.  The slope gives 
the power law exponent ݊=1.00504.  (d) The viscosity of water vs. shear rate at 20°C, 
using ܵ=13.6 to let the water viscosity match with 1.002cP at 20°C. 
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                                      (a)                                       (b) 
 
 
                                     (c)                                      (d) 
Figure 2-35: The viscosity measurement of human whole blood in a channel with 
݄=30µm and ݓ=120µm at 20°C.  (a) The blood column length ܮ vs. time ݐ.  (b) The 
mean blood advancing velocity ݒ vs. time ݐ.  (c) The log-log plot of 1/ܮ versus ݒ, giving 
݊=0.82183.  (d) The blood viscosity vs. shear rate.  Shear rates range from 77.5s-1 to 
9868.6s-1. 
The measurement data for the viscosities of human whole blood are in good 
agreement with the published data [81] (Table 2-10), assuming the hematocrit is 45% 
since it is the normal value for men. 
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Table 2-10: The measured viscosities of human whole blood at 20°C at different shear 
rates based on the power law and Carreau-Yasuda viscosity models, compared with the 
published data for 45% hematocrit [81]. 
Shear rate (1/s) 
Measured viscosity (cP) Published 
viscosity data (cP) 
at 22°C [81] Power law Carreau-Yasuda 
77.54 9.97±0.3 9.29 ~9.2 
105.74 8.58±0.3 8.73 ~8.6 
123.36 8.29±0.2 8.47 ~8.3 
155.08 7.74±0.1 8.11 ~8.1 
183.27 7.22±0.4 7.87 ~7.8 
211.47 7.47±0.7 7.67 ~7.6 
 
The extension of this approach to the viscosity measurement of adult zebrafish 
whole blood is shown in Figure 2-36. 
The measured blood viscosity of adult zebrafish is quite linear in the range of 
shear rates produced in the test, and smaller than that of human, which is very likely due 
to the fact that the hematocrit is only about 31% for zebrafish blood [82], but takes a 
higher value, about 40-45%, for human blood, and the viscosity increases with the 
hematocrit level in the blood.  The estimated values of the parameters in the Carreau-
Yasuda constitutive viscosity model for both human and zebrafish blood are summarized 
in Table 2-11.  The estimated parameters for the non-Newtonian viscosity models are 
only suitable for the ranges of shear rates produced in the tests. 
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                                     (a)                                       (b) 
 
 
                                      (c)                                       (d) 
Figure 2-36: The viscosity measurement of unadulterated adult zebrafish whole blood in 
a channel with ݄=30µm and ݓ=120µm at 20°C.  (a) The blood column length ܮ vs. time 
ݐ.  (b) The mean blood advancing velocity ݒ vs. time ݐ.  (c) The log-log plot of 1/ܮ 
versus ݒ, giving ݊=0.99814.  (d) The viscosity vs. shear rate.  Shear rates range from 
184.2s-1 to 15399.9s-1. 
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Table 2-11: The estimated values of the fitting parameters in the Carreau-Yasuda model 
for both human and zebrafish whole blood at 20°C. 
Model The viscosity function ࢌሺࢽሶ ሻ Parameters Human blood Zebrafish Blood
Carreau-
Yasuda 
1
ሾ1 ൅ ሺߣߛሶሻ௔ሿሺଵି௡ሻ ௔⁄
ߟ଴ (cP) 65.7 45.26 
ߟஶ (cP) 4.0558 3.617 
ߣ (s) 10.396 10.400 
݊ 0.63151 0.34003 
ܽ 1.76 1.76 
 
2.6 Summary and Conclusion 
This chapter first reports the study of in-situ deposition temperature (from 20°C to 
80°C) effects on parylene C properties.  At higher deposition temperature, the as-
deposited parylene C thin film exhibited higher glass transition temperature and β-
relaxation temperature, as a result of smaller percentage of amorphous phase and 
increasingly ordered polymer chains.  XRD scanning data indicated that higher 
deposition temperature induced greater degree of crystallinity because of more thermal 
energy available for the crystallization.  And the polymer also became stiffer due to less 
flexible polymeric chains, indicative of larger Young’s modulus.  From these new data, it 
is concluded that parylene C’s properties could be tailored to specific application 
requirements by choosing the right deposition temperature. 
Then this chapter presents another application of in-situ heated parylene 
deposition: improving the diffusion and penetration of parylene into PDMS.  The surface 
mobility of parylene monomer is a strong increasing function of temperature so the 
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gaseous monomer tends to diffuse further inside the PDMS pore at elevated deposition 
temperatures.  The enhanced pore sealing capability of parylene at elevated deposition 
temperatures can increase the adhesion between parylene and silicone.  The PDMS pore 
diameter was estimated to be 6.02nm according to the nonlinear theoretical modeling and 
experimental SIMS curves.  The experimental data of the mechanical and barrier 
properties of the hybrid parylene/PDMS material agree very well with the results derived 
from the composite material theory, suggesting that the parylene coatings inside PDMS 
pores contribute very little to the macroscopic mechanical or barrier properties of the 
hybrid parylene/PDMS material. 
Deposition of parylene inside a microchannel holds promising applications in the 
surface treatment of PDMS microfluidic device.  Then this chapter studied the effects of 
the dimer type, dimer loading weight, substrate temperature, and channel size on the 
penetration preformation.  Based on the preliminary experimental and theoretical results, 
parylene can penetrate into the microchannel and protect the inner surfaces better at 
elevated deposition temperatures.  Further studies on the PDMS porosity and the parylene 
deposition into PDMS pores are required to achieve a more accurate boundary condition 
for a comprehensive understanding on this diffusion-reaction system. 
Finally, the first experimental study on the non-Newtonian viscosity of adult 
zebrafish whole blood was presented using a proposed capillary pressure-driven PDMS 
viscometer.  This viscometer demanded small amount of samples, provided fast 
measurement, and produced a wide range of shear rates during a single run.  After the 
device calibration with water, the viscosity measurement of human whole blood resulted 
in very good agreement with published data, demonstrating the reliability of the device.  
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The whole blood viscosity of zebrafish was found smaller than that of human, likely 
attributed to the smaller hematocrit for zebrafish blood. 
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CHAPTER 3 OXYGEN 
TRANSPORTER 
3.1 Overview 
For the first time, a paradigm shift in the treatment of retinal ischemia is proposed: 
providing localized supplemental oxygen to the ischemic tissue via an implanted MEMS 
device.  A passive MEMS oxygen transporter was designed, built, and tested in both 
artificial eye models and porcine cadaver eyes to confirm various hypotheses.  The finite 
element modeling results predicted that the proposed approach would be very promising 
to cure diabetic retinopathy. 
In the United States, the leading cause of blindness is diabetic retinopathy [5], 
which results in retinal ischemia (i.e., inadequate blood flow), and retinal hypoxia (i.e., 
lack of oxygen), ending in irreversible retinal nerve cell degeneration or death.  
Unfortunately, current treatments of diabetic retinopathy have significant drawbacks.  
Laser photocoagulation results in a constricted peripheral visual field as well as delayed 
dark adaptation [20], while pars plana vitrectomy increases the risk of iris 
neovascularization as well as elevated intraocular pressure [21].  However, localized, 
supplemental intravitreal oxygen therapy has been proposed as a therapy for retinal 
ischemia [22].  This is done by delivering supplemental oxygen locally to the hypoxic 
tissue and preventing the progression of the ischemic cascade.   
The basic anatomy of the eye is shown in Figure 3-1.   
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Figure 3-1: The eye anatomy. 
In this chapter, a MEMS device (i.e., MEMS oxygen transporter) was designed to 
transport oxygen from an oxygen-rich space to the oxygen-deficient vitreous humor and 
then to the ischemic retina. 
First, the oxygen permeability of silicone was measured using a custom setup.  Its 
high oxygen permeability allows fast passage of oxygen, making it an ideal material for 
the device.  Then artificial eye models were made to simulate the diffusive behavior of 
oxygen in the static vitreous gel and the saccade-induced convective transport of oxygen 
in the vitreous chamber following vitrectomy.  The latest research has led to a finding 
that the vitreous consumes oxygen due to the antioxidative capacity of ascorbate acid in 
the vitreous humor [83].  The reaction kinetics of the ascorbate-dependent oxygen 
consumption was studied via measuring the decay of oxygen tension in vitreous samples 
of porcine cadaver eyes, and confirmed using our device as an oxygen source in porcine 
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cadaver eyes.  Finally, finite element modeling was used to analyze the three-dimensional 
oxygen distribution in the human eye, suggesting that the proposed approach can restore 
the oxygen partial pressure ( ݌ܱଶ ) in the macula as well as the retinal oxygen 
consumption rate (i.e., the oxidative metabolic rate) to above the critical levels for retinal 
ischemia. 
3.2 Device Design and Fabrication 
3.2.1 Device	Design	
The device consists of three major components (Figure 3-2): a bag (placed 
underneath the permeable conjunctiva and resting on the impermeable sclera), a cannula 
(penetrating the sclera at the pars plana), and a diffuser (placed in the posterior vitreous).   
 
 
                               (a)              (b)                   
Figure 3-2: (a) The device components and placement in the eye.  The bag is placed 
underneath the conjunctiva and rests on the sclera; the cannula penetrates the sclera at the 
pars plana; the diffuser is placed in the posterior vitreous.  (b) An example of a finished 
device with a cannula length of 12mm.   
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The ݌ܱଶ was measured to be about 100mmHg underneath the conjunctiva for a 
rabbit when the eye was open, and around 15mmHg in the vitreous humor.  The ݌ܱଶ 
gradient will drive sub-conjunctival oxygen to permeate into the bag, transport along the 
cannula and diffuse into the vitreous and then to the retina.  The diffuser is designed to 
enter through a 3mm-long surgical incision by folding it.  The cannula encapsulates a 
type 304 stainless steel tube (OD = 0.02in, ID = 0.016in) that can be bent to hold the 
device on and inside the eye as in Figure 3-2.  An example of a finished device is shown 
in Figure 3-2. 
3.2.2 Device	Fabrication	
The device fabrication consists basically of two process steps: mold fabrication 
and silicone casting (Figure 3-3).  For the mold fabrication, three layers of negative dry 
film photoresist (WBR2120, single-layer thickness 120µm, DuPontTM) were laminated on 
a fresh silicon wafer, followed by post-lamination baking (65°C, 20min), UV light 
exposure (400mJ/cm2), and development (AZ340 developer:DI water = 1:4, 40min), 
defining the side walls of the device.  Then a second three-layered lamination followed 
by the same lithography process defined the top and bottom flat walls of the device.  The 
resulting mold was coated with parylene C for the easy release of subsequent silicone cast 
due to week adhesion between them.  For the casting of silicone (MED4-4210, two-part, 
medical-grade, NuSil Technology LLC), base and curing agent were mixed at a 10:1 ratio 
by weight, degassed under vacuum, and applied onto the patterned mold.  Excess silicone 
on the surface of the mold was removed, leaving silicone only inside the trenches of the 
mold.  This was followed by a partial curing at 65°C for 30min.  The resulting partially 
cured silicone cast was only one half of the final device.  A type 304 stainless steel tubing 
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of desired length (e.g., 12mm) was cut and assembled together with two silicone casts 
such that it was inside the cannula of the final device.  The assembly utilized uncured 
silicone followed by fully curing (100°C, 8 hours) as the glue to produce an enclosed 
chamber as the final device.   
 
 
(a) 
 
 
(b) 
 Figure 3-3: (a) The fabrication process for the oxygen transporter device.  (b) The 
geometry and dimensions of the device.   
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The geometry and dimensions of the device (Figure 3-3) remain the same 
throughout the section 3.3.  This device will work as a medical implant, and its 
biocompatibility is ensured by the fact that the device contains only medical-grade 
materials, including silicone (MED4-4210, medical-grade, NuSil Technology LLC), type 
304 stainless steel, and parylene C coatings partially, which are well known for good 
biocompatibility.   
3.3 Experiments, Characterization, and Computational Modeling 
3.3.1 Oxygen	Permeability	of	Silicone	
First, we measured the oxygen permeability of the silicone MED4-4210 from the 
Nusil company using a custom setup as schematically shown in Figure 3-4.   
 
 
Figure 3-4: A schematic drawing of the experimental setup to measure the oxygen 
permeability of silicone using the dynamical accumulation method. 
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A silicone film was attached to a gas chamber (the permeation cell), which was 
flushed with pure oxygen.  The other side of the film was left open to the atmosphere, 
where ݌ܱଶ  is about 160mmHg (~21% oxygen).  Oxygen permeated from the gas 
chamber, the side with high oxygen concentration, through the silicone film, and into the 
atmosphere, the side with lower oxygen concentration.  The pressure inside the gas 
chamber decreased with time and was measured by a pressure gauge. 
The well-known relationship used to describe gas permeation through packaging 
films can be expressed as, 
 ݆ ൌ െ݌෤׏݌ܱଶ, (3-1)
where ݆  is the molar flux of gas permeation, ݌෤  is the permeability coefficient of the 
permeant gas through the film, and ׏݌ܱଶ  is the applied partial pressure gradient of 
oxygen across the sample film. 
The molar concentration of oxygen ܿ can be converted to ݌ܱଶ using Henry’s law 
of solubility,  
 ݌ܱଶ ൌ ܭுܿ, (3-2)
where ܭு is the Henry constant. 
The famous Fick’s law for oxygen diffusion is given as, 
 ݆ ൌ െܦ׏ܿ, (3-3)
where ܦ is the diffusion coefficient of oxygen. 
Combining eqns. (3-1) - (3-3), we can derive the relationship between the 
permeability, the diffusivity and the solubility of oxygen,  
 ݌෤ ൌ ܦܭு. (3-4)
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The oxygen permeability of silicone was estimated from the data collected during 
the experiments using the following model that was developed from eqn.  (3-1) [84], 
 ܱ݀݊ଶ௧݀ݐ ൌ െ
݌෤ܣ
݈ ൫݌ܱଶ
௧ െ ݌ܱଶ௔௠௕௜௘௡௧൯, (3-5)
where ܱ݊ଶ௧  is the moles of oxygen in the gas chamber at time ݐ , ܣ  is the sample’s 
permeation area, ݈ is the sample’s film thickness, ݌ܱଶ௔௠௕௜௘௡௧ is the ݌ܱଶ in the atmosphere, 
160mmHg, and ݌ܱଶ௧ is the ݌ܱଶ in the gas chamber at time ݐ.  Eqn. (3-5) describes the rate 
at which oxygen permeates through a sample of known area and thickness under a 
driving force defined by the partial pressure difference across the sample.  The 
differential partial pressure ݌ܱଶ௧ െ ݌ܱଶ௔௠௕௜௘௡௧ was measured by a pressure gauge. 
It may be safely assumed that the volume of the permeation chamber remained 
constant throughout the measurement.  Oxygen partial pressure is directly related to 
moles of oxygen via the ideal gas law, 
 ݌ܱଶ௧ ൌ ܱ݊ଶ
௧ܴܶ
ܸ , (3-6)
where  ܸ is the total volume of the gas chamber, ܴ is the universal gas constant, and ܶ is 
the room temperature, 293.15K.  The substitution of eqn. (3-6) into eqn. (3-5) yields,  
 ݀݌ܱଶ௧݀ݐ ൌ െ
ܴܶܣ݌෤
ܸ݈ ൫݌ܱଶ
௧ െ ݌ܱଶ௔௠௕௜௘௡௧൯. (3-7)
Integrating eqn. (3-7) from the beginning of the experiment (ݐ=0) to time ݐ yields,  
 ln ቆ݌ܱଶ
௧ െ ݌ܱଶ௔௠௕௜௘௡௧
݌ ଶܱ଴ െ ݌ ଶܱ௔௠௕௜௘௡௧ቇ ൌ െ
ܴܶܣ݌෤
ܸ݈ ݐ. (3-8)
Eqn. (3-8) suggests that the plot of the natural logarithm of 
൫݌ܱଶ௧ െ ݌ܱଶ௔௠௕௜௘௡௧൯ ൫݌ܱଶ଴ െ ݌ܱଶ௔௠௕௜௘௡௧൯ൗ  versus time ݐ  is a straight line with a slope 
proportional to the permeability coefficient,  
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 ݌෤ ൌ |ݏ݈݋݌݁|ܸ݈ܴܶܣ . (3-9)
The oxygen permeability ݌෤ was determined from the absolute slope of the plot 
lnൣ൫݌ܱଶ௧ െ ݌ܱଶ௔௠௕௜௘௡௧൯/൫݌ܱଶ଴ െ ݌ܱଶ௔௠௕௜௘௡௧൯൧  vs. time ݐ , shown by eqn.  (3-9).  The 
measurement result of a typical test is shown in Figure 3-5.  The mean oxygen 
permeability of the silicone MED4-4210 over three tests is determined to be 
(3.490.78)104µL·µm/(mm2·day·atm). 
 
 
Figure 3-5: A plot of lnൣ൫݌ܱଶ௧ െ ݌ܱଶ௔௠௕௜௘௡௧൯/൫݌ܱଶ଴ െ ݌ܱଶ௔௠௕௜௘௡௧൯൧ vs. time ݐ from a test, 
in which the oxygen permeability ݌෤  of the silicone MED4-4210 is determined to be 
4.04104µL·µm/(mm2·day·atm). 
3.3.2 Flow	Resistances	of	the	Proposed	Oxygen	Delivery	System	
We define the oxygen flow resistance ܴ as the ratio of the oxygen partial pressure 
difference ∆݌ܱଶ between the upstream and the downstream, to the oxygen molar flow 
rate ܳ, 
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 ܴ ൌ ∆݌ܱଶܳ . (3-10)
There are four major transport processes for the oxygen delivery by the device, 
thus four corresponding flow resistances: ܴଵ , the resistance of permeation of sub-
conjunctival oxygen ( ݌ܱଶ =100mmHg) into the bag; ܴଶ , the resistance of oxygen 
diffusion along the cannula; ܴଷ, the resistance of oxygen permeation out of the diffuser; 
ܴସ, the resistance of oxygen diffusion to the ischemic retina (݌ܱଶ=0) through the vitreous 
(Figure 3-6).  ܴଵ  and ܴଷ  were calculated based on eqn. (3-5), requiring the measured 
oxygen permeability of silicone, 
 ܴଵ ൌ ݈݌෤ܣଵ, (3-11)
 ܴଷ ൌ ݈݌෤ܣଷ, (3-12)
where ݈ is the thickness of silicone, 360µm, ܣଵ is the permeation area of the bag, and ܣଷ 
is the permeation area of the diffuser.   
ܴଶ  was calculated based on the one-dimensional Fick’s law, in which the 
diffusion coefficient is the oxygen-air binary diffusivity at 25°C and 1atm, 0.2cm2/s.  In 
order to determine ܴସ based on the Fick’s law of mass diffusion and the Henry’s law of 
solubility, we ran a three-dimensional finite element simulation using COMSOL 
Multiphysics 4.4 due to the complexity of the eyeball geometry.  In the simulation, the 
݌ܱଶ  was set to zero at the vitreoretinal interface (i.e., the worst case), the dissolved 
oxygen diffusivity in water was set to 210-5cm2/s at 25°C, assumed to be the same as 
that in the vitreous since about 99% of the vitreous is water, and the Henry constant ܭு 
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for oxygen in water was set to 769.2L·atm/mol at 25°C, also assumed to be equal to that 
for oxygen in the vitreous. 
 
     
          (a)              (b) 
Figure 3-6: (a) The four major oxygen transport processes of the oxygen delivery by the 
device and their corresponding flow resistances.  (b) The circuit model for the four 
oxygen transport processes.  The flow resistances ܴଵ, ܴଶ, and ܴଷ are calculated by theory, 
and ܴସ by finite element simulation based on the Fick’s law of diffusion because of the 
complexity of the eyeball geometry.  Oxygen diffusion to the retina through the vitreous 
turns out the most limiting transport process. 
The calculated values of ܴଵ–ܴସ  and a circuit model for the oxygen transport 
processes as a series combination of ܴଵ –ܴସ  are shown in Figure 3-6.  Here, ܴସ  is 
significantly larger than all the other three resistances, suggesting that the oxygen 
diffusion in the vitreous is the most limiting process.  Assuming the ݌ܱଶ is 100mmHg in 
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the sub-conjunctival space, the ݌ܱଶ at the interface of the diffuser and the vitreous was 
calculated to be 98mmHg for the worst case, i.e., ݌ܱଶ=0 at the vitreoretinal interface, 
which means that the device is highly efficient in terms of transporting oxygen from an 
oxygen-rich space to the diffuser, which should be placed very close to the ischemic 
retina, especially the macula, the area of the retina that is responsible for sharp, central 
vision. 
3.3.3 Artificial	Eye	Model	Experiments	
Artificial human eye models of the same dimensions as in the reference [85] were 
created in hard silicone, and then filled up with deoxygenated water (݌ܱଶ = 15mmHg 
initially).   
3.3.3.1 In the Atmosphere 
Before performing any experiments in the atmosphere, the artificial eye model 
was coated with epoxy to prevent any oxygen exchange through the shell of the eye 
model, hence imposing a no-flux boundary condition (BC).  With a fabricated device 
mounted into the eye model and exposed to the atmosphere where ݌ܱଶ=160mmHg, the 
݌ܱଶ in the water at a point 3mm away from the diffuser was measured by an oxygen 
sensor (NeoFox-GT, Ocean Optics, Inc.).  The schematic drawing of the measurement of 
݌ܱଶ in the eye model with the device exposed to the open air is shown in Figure 3-7. 
The four major oxygen transport processes were modeled by a single three-
dimensional COMSOL simulation.  In the numerical simulation, the oxygen permeation 
process consisted of two steps: oxygen dissolution into the silicone and oxygen diffusion 
inside the silicone.  Eqn. (3-4) was used to calculate the Henry constant for oxygen in 
silicone according to the measured oxygen permeability of the silicone MED4-4210 ݌෤ 
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and the typical oxygen diffusion coefficient in silicone, ܦ=7.8810-5cm2/s [86].  Both 
݌ܱଶ  and oxygen molar fluxes were set to be continuous across the silicone-air and 
silicone-water/vitreous interfaces during the simulation.  The wall of the stainless steel 
tube was modeled as a zero-thickness impermeable material. 
      
     (a)            (b)  
Figure 3-7: (a) The schematic of the measurement of ݌ܱଶ  in the eye model with the 
device exposed to the open air.  (b) A photo of the custom setup.   
To simulate the saccade-induced convective transport of oxygen, the eye model 
was shaken with sinusoidal rotation at a frequency of 5Hz and amplitudes of 5° and 20°, 
respectively. The rotation was controlled by a servomotor connected to a programmable 
microcontroller board (Arduino Uno), inducing rapid periodic convective motion of 
water in the eye model.  The measurement of ݌ܱଶ was done at the same point as in the 
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static case, and the plots in Figure 3-8 show a significantly faster ݌ܱଶ increase for the 
rotation of the eye model, demonstrating the saccade-enhanced transport effect.   
 
  
 
(a) 
 
 
(b) 
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(c) 
Figure 3-8: (a) The experimental and simulation results of the ݌ܱଶ 3mm away from the 
diffuser as a function of time for the static eye model and the eye model under 5Hz 
rotation with amplitudes of 5° and 20°, respectively.  (b) The simulation results of ݌ܱଶ 
profiles on the equatorial planes at ݐ=0.8hr (upper) and 11.6hr (lower) for the static case.  
(c) The simulation results of average flow streamlines on the equatorial (upper) and 
vertical planes (lower) of the eye model for the 20° rotation. 
The three-dimensional unsteady saccade-induced laminar flow of water in the eye 
model was modeled by computational fluid dynamics based on the incompressible 
Navier-Stokes equation and the moving mesh method.  The average flow streamlines on 
the equatorial and vertical planes of the eye model for the 20° rotation over one period 
were obtained when the flow field became periodic with time (Figure 3-8). 
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3.3.3.2 In the Nitrogen Glove Box 
 
 
(a) 
 
 
(b) 
Figure 3-9: (a) The schematic drawing of the experimental setup.  (b) A photo of the 
setup. 
An artificial eye model with a fabricated device mounted into it was filled up with 
water, and then put inside a glove box, which was purged with pure nitrogen gas such 
that the ݌ܱଶ  was 0 inside the glove box.  The device bag was still exposed to the 
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atmosphere where the ݌ܱଶ was 160mmHg.  Then we measured the ݌ܱଶ in the water at 
points 0.5, 1.5, 2.5, 3.5, 4.5, and 5.5mm away from the device diffuser using the oxygen 
sensor.  The schematic drawing and a photo of the experimental setup are shown in 
Figure 3-9.   
The four major oxygen transport processes were again modeled by a single three-
dimensional COMSOL simulation in which the boundary condition for the artificial eye 
model was changed to ݌ܱଶ=0, but the device bag was still exposed to the atmosphere 
where the ݌ܱଶ was 160mmHg.  The experimental and simulation results are shown and 
compared in Figure 3-10, and the simulation results are in very good agreement with the 
measurement data. 
 
  
(a)      (b) 
Figure 3-10: (a) The steady ݌ܱଶ profile in the equatorial plane of the eye model for the 
nitrogen glove box experiment, and ݀ is the distance between the oxygen sensor tip and 
the device diffuser.  (b) The measurement and simulation data of ݌ܱଶ in the water for ݀ 
ranging from 0.5 to 5.5mm. 
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3.3.4 Porcine	Cadaver	Eye	Experiments	
Porcine cadaver eyes (Sierra Medical Inc.) were used to verify our results in vitro.  
First, the ascorbate-mediated oxygen consumption rate versus ݌ܱଶ  was measured in a 
vitreous sample collected with a vitrector.  The reaction kinetics [87] can be best 
described by a pseudo-first-order rate equation since the vitreous ascorbate is supplied in 
great excess and its concentration remains constant, which is valid in healthy 
physiological conditions.  The vitreous oxygen consumption rate was then modeled as 
having a linear dependence on the oxygen molar concentration, and thus ݌ܱଶ as well 
(Figure 3-11). 
 
 
Figure 3-11: The experimental data of oxygen consumption rate vs. ݌ܱଶ in the vitreous 
gel of porcine cadaver eyes, curve-fitted by a first-order reaction rate model.   
113 
 
   
      (a)            (b) 
 
 
(c) 
Figure 3-12: In-vitro porcine cadaver eye experiments.  (a) A photo of a porcine cadaver 
eye with a device mounted into it.  (b) The simulation result of the steady ݌ܱଶ profile in 
the equatorial plane of the porcine cadaver eye.  And ݀  is the distance between the 
oxygen sensor tip and the device diffuser.  (c) The measurement and simulation data of 
the ݌ܱଶ in the vitreous of a porcine cadaver eye for ݀ ranging from 0 to 5mm. 
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With a fabricated device mounted into a porcine cadaver eye, steady ݌ܱଶ values 
in the vitreous at points ranging from 0 to 5mm away from the diffuser were obtained 
using the oxygen sensor (Figure 3-12).   
A single three-dimensional COMSOL simulation for all the oxygen transport 
processes was performed; however, the chamber radius was changed from 12mm to 9mm 
that is closer to the realistic size of the porcine cadaver eye, and the vitreous oxygen 
consumption was included using a first-order reaction kinetics.  The simulation results 
are in very good accordance with the measurement data (Figure 3-12).   
3.4 3D Simulation of Oxygen Transport Processes in the Human Eye 
The basic anatomy of the human eye is shown in Figure 3-13. 
 
 
Figure 3-13: The anatomy of the human eye. 
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Figure 3-14: The schematic of the geometric model of the posterior eye. 
In this section, the oxygen transport processes in the human eye were modeled by 
a single three-dimensional finite element simulation using COMSOL.  The aim of this 
section is to simulate the oxygenation of the whole retina when our device is implanted 
into the eye and the retina is subjected to various degrees of ischemia. 
An axisymmetric three-dimensional geometric model of the human posterior eye, 
fairly close to those used in previous studies as validated anatomically and 
physiologically correct models [[88-90], is shown in Figure 3-14.  The major volume of 
the human eye is filled with vitreous humor, which is a gel-like substance bounded by the 
hyaloid membrane, the retina, and the lens.  The vitreous cavity is deformed in the front 
due to the posterior lens curvature while the most portion of the boundary is attached to 
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the retina tissue.  The hyaloid membrane spans the gap between the lens and the ciliary 
body. 
The radii of curvature of the retina and the lens in the human eye were taken to be 
8.5mm and 5.5mm, respectively.  The center of curvature of the retina is 6.1mm posterior 
to the hyaloid membrane boundary, and the center of curvature of the lens is 2.4mm 
anterior to the hyaloid membrane.  The retina spans from the posterior pole to the ora 
serrate, forming an angle of 106°, and the total thickness of the retina is 251µm.  The 
outer retina was divided into three regions of which only one was set to have 
consumption.  The inner retina was considered as one uniform region with respect to 
maximal rate of oxygen consumption and blood flow.   
The oxygen transport in the human eye was modeled by a three-dimensional 
COMSOL simulation, taking into account first-order lens oxygen consumption [88], 
ascorbate-mediated vitreous oxygen consumption [88], and oxygen supply and 
consumption in the retina based on a four-layered model [91].   
3.4.1 Modeling	of	Oxygen	Transport	in	the	Vitreous	
In the normal human eye, the vitreous gel can be treated as a static, 
incompressible porous medium, and the lens is separated from the retina by the 
transparent, acellular vitreous body.  Functions attributed to the vitreous gel include 
driving growth of the eye during embryonic development and acting as a viscoelastic 
mechanical damper following birth [92].  Although the gel is initially homogeneous, 
aging leads to structural anisotropy and degeneration in the vitreous body.  This process 
is characterized by the formation of fluid-filled spaces in the central vitreous, detachment 
of the vitreous from the retina, and an overall loss in water content [93-95].  Although 
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vitreous degeneration, or liquefaction, usually occurs without incident, persistent 
adhesion at the vitreoretinal interface can lead to retinal tears, detachments, macular holes, 
and epiretinal membranes [96].  Even when gel liquefaction and posterior vitreous 
detachment occur without incident to the retina, pathophysiological changes accrue at the 
lens.  A potential reason for this is that vitreous liquefaction or surgical removal of the 
vitreous gel through pars plana vitrectomy increase convective motion and fluid 
circulation in the vitreous chamber, which enhances transport of oxygen from the retina 
to the lens [97].  Because the retina requires a continuous supply of oxygen to support 
visual processes and the lens is normally in a hypoxic environment, oxygen gradients 
exist across the vitreous body in vivo.  Following vitrectomy, oxygen content increases 
near the posterior lens capsule [98], thereby increasing the risk for oxidative damage and 
the concurrent development of nuclear cataracts [99].  Coupled with the recently 
demonstrated ability of ascorbate in the vitreous gel to consume oxygen [83], these 
studies collectively indicate a protective role for the intact vitreous in preventing nuclear 
sclerotic cataracts. 
The vitreous humor is bounded on the anterior surface by the lens and the hyaloid 
membrane, and the retina on the posterior surface. 
The steady-state oxygen transport was modeled using the Fick’s law of diffusion.  
In certain cases, as discussed later, we included the effects of convective motion to justify 
the assumptions made about the absolute diffusivity of the system.  The differential form 
of the continuity equation (the mass balance equation) with the Fick’s law of diffusion is, 
 ߲߲ܿݐ ൅ ܝ ∙ ׏ܿ ൌ ܦ׏
ଶܿ െ ݍ, (3-13)
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where ܿ is dissolved oxygen concentration, ܝ is the velocity vector, ܦ is the diffusion 
coefficient for dissolved oxygen in the vitreous, and ݍ is the ascorbate-mediated oxygen 
consumption of the vitreous.  Since the vitreous is approximately 99% in water, we 
choose ܦ = 4×10-5cm2/s which is the typical value for oxygen diffusion in water [88].  
The Henry’s law, eqn. (3-2) is used to convert oxygen partial pressure (݌ܱଶ ) to 
concentration, and the Henry constant for oxygen in water is 769.2L·atm/mol [88]. 
Ascorbate-mediated oxygen consumption ݍ  in eqn. (3-13) can be reasonably 
approximated by a hyperbolic function analogous to Michaelis-Menten kinetics [88],  
 ݍ ൌ ܽ݌ܱଶܾ ൅ ݌ܱଶ, (3-14)
where ܽ and ܾ are both constants, and their values for different vitreous conditions are 
listed in Table 3-1. 
Table 3-1: The values of ܽ and ܾ in the hyperbolic regressions that provide estimates for 
concentration-dependent rate of ascorbate-mediated oxygen consumption in the vitreous 
body with different conditions [88]. 
Vitreous conditions Parameter Value 
intact 
ܽ (µL/mL/hour) 1.57 
ܾ (mmHg) 27.48 
liquefied 
ܽ (µL/mL/hour) 0.68 
ܾ (mmHg) 11.29 
vitrectomy 
ܽ (µL/mL/hour) 0.67 
ܾ (mmHg) 11.89 
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3.4.2 Saccade‐Induced	Convective	Transport	of	Oxygen	
The posterior chamber of the eye is filled up with the vitreous gel, a transparent 
highly (99%) hydrated material with viscoelastic properties.  The vitreous provides 
structural support to the eye, and promotes the adherence between the retina and the 
choroid (the vascular layer between the retina and the sclera).  It also acts as a diffusion 
barrier for heat and mass (e.g., oxygen) transport between the posterior and anterior 
segments of the eye.  Some of these functions are affected when the vitreous loses its 
structural homogeneity during the natural aging process.  During this aging process, the 
vitreous undergoes a progressive liquefaction process called synchysis, such that it loses 
its gel-like structure and its elastic properties, becoming a viscous liquid [93].  The 
vitreous mobility increases with the degree of liquefaction.  In addition, to treat certain 
eye conditions such as retinal tears and diabetic retinopathy, a vitrectomy, a surgical 
procedure in which the vitreous is removed, and the posterior chamber is refilled with a 
vitreous substitute such as silicone oil, balanced salt solution (BSS), a perfluorocarbon 
liquid, and even aqueous humor, is performed [100].  After vitreous liquefaction or 
vitrectomy, the fluid motion relative to the eye wall is characterized by higher velocities, 
since the vitreous chamber contains a purely viscous fluid, with no elastic behavior.  The 
presence of the viscous liquid in the vitreous chamber, either due to liquefaction or as a 
result of vitrectomy, could potentially impact heat/mass transport in the posterior eye.  
For example, an increase in incidence of nuclear cataracts in vitrectomized eyes has been 
observed, and the findings are attributed to elevated oxygen levels close to the lens [98].  
Saccades are rapid eye oscillations, allowing us to redirect the line of sight and refocus 
regularly at different locations.  Since saccades happen rapidly, the vitreous sloshing 
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velocities could be high, resulting in significant convective transport [101-103].  The 
effect of real saccade movements on the motion of liquefied vitreous and the distribution 
of intravitreal injected drug has been investigated, and the transport and dispersion of 
intravitreal injected drug for various saccade amplitudes have also been studied [104].  
However, in order to simply the simulation of convective transport of oxygen in the 
vitreous but without losing much accuracy, the convection-enhanced transport effect has 
been simulated by increasing the absolute diffusivity for oxygen in the vitreous body [88].  
With the increasing diffusivity, oxygen content was nearly homogeneous in the core of 
the vitreous with steep concentration gradients present near the retina and lens.  Two-fold 
and 10-fold increases in the diffusion constant are used in later simulations of “low” and 
“high” liquefaction, respectively.  Similar trends were observed with random motion 
prescribed in the core of the vitreous.  Here, we will use the similar idea to account for 
the saccade-induced convective transport effect, as shown in Table 3-2 [88].   
Table 3-2: The equivalency between the vitreous motion velocity and the increasing 
oxygen diffusivity based on finite element simulation [88]. 
Maximum magnitude of 
velocity for random 
vitreous motion (mm/s) 
Equivalent diffusion 
constant for oxygen in the 
vitreous (cm2/s) 
Note 
0 4×10-5 1X, baseline 
0.1 8×10-5 2X, liquefaction (low) 
0.5 1.6×10-4 4X, liquefaction (medium) 
1 4×10-4 10X, liquefaction (high) 
5 1×10-3 25X 
10 4×10-3 100X 
50 4×10-2 1000X 
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3.4.3 Modeling	of	Oxygen	Consumption	by	the	Lens	
Oxygen consumption has not been measured in physiologic conditions in the 
human lens.  However, a recent study in humans found increased oxygen content at 
locations anterior and posterior to the lens following cataract surgery compared with 
having an intact lens, suggesting that human lens tissue consumes oxygen [105].  In vitro 
studies in guinea pig and cow have also shown that the lens consumes oxygen, but 
consumption rates were measured in nonphysiologic (hyperoxic) conditions [106].  
Alternatively, in an in vivo rabbit study, a relatively linear relationship between oxygen 
content and consumption rate was found across the posterior lens surface in normoxic 
conditions [107].  Importantly, ascorbate-mediated oxygen consumption is small in 
rabbits, which permits consumption rates at the posterior surface of the lens to be 
calculated directly without correcting for consumption in the vitreous [83, 108].  As a 
first order approximation, this linear relation was used to guide the consumption (outflow) 
boundary condition at the posterior side of the lens, which is chosen to be 
0.02µL/hour/mmHg [88]. 
3.4.4 Modeling	of	Oxygen	Transport	in	the	Retina	
The anatomy of the retina is shown in Figure 3-15.  For convenience, the retina is 
often thought of as two domains: the outer retina (avascular) and the inner retina 
(supplied with blood).  The outer, avascular, part is mainly nourished by diffusion from 
the choroid that has a high blood supply not sensitive to metabolic regulation.  The inner 
half is vascularized by a system highly sensitive to metabolic feedback from the tissue, 
and composed of a complex network of oxygen sources (arteries, arterioles) and sinks 
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(veins, venules) of variable length, diameter, tortuosity, and branching that vary between 
individuals [109].   
 
 
Figure 3-15: The retina anatomy. 
Based on experimental studies [110, 111], the obtained results from mathematical 
modeling of the whole retina [91] confirmed the reasonability of experimental findings 
on oxygen consumption and supply.  We modeled the whole retina using a four-layer 
model, and the oxygen consumption was set to obey Michaelis–Menten kinetics [91]. 
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Figure 3-16: The geometric model of the retina.  Regions 1, 2, and 3 belong to the outer 
retina (avascular) while region 4 encompasses the whole inner retina (vascular). 
The outer retina was divided into three regions (Figure 3-16).  The outer retina, 
regions 1–3, is supplied with oxygen through diffusion only, mainly from the choroid.  
Region 1 contains the outer segments of the photoreceptors, region 2 the inner segments, 
and region 3 the outer nuclear layer.  The vast majority of the oxygen consumption in the 
outer part of the retina takes place in the inner segmental layer since the inner segments 
of the photoreceptors contain most of the mitochondria.  This region, labeled region 2, 
was considered to occupy 20% of the outer retina and to have its inner and outer 
geometric boundaries at 75 and 85% of the retinal thickness, respectively [112].  Thus, 
the oxygen consumption by the outer retina was confined to region 2.  Accordingly the 
regions 1 and 3 have no oxygen consumption.  The inner retina, labeled region 4, 
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contains the deep retinal capillaries, the outer plexiform layer, the inner nuclear layer, the 
outer region of the inner plexiform layer, the inner region of the inner plexiform layer, 
the ganglion cell/nerve fiber layer, and the superficial retinal capillaries.  In the inner 
retina the oxygen consumption was set to be uniformly distributed and the oxygen to be 
transported to the cells via the blood and by diffusion.  The thickness of the whole retina 
was set to 251μm [112].   
The change in the local partial pressure of oxygen is given by the continuity 
equation and the well-known Fick’s law of diffusion equation, 
 ݀݌ܱଶ݀ݐ ൌ ܦ׏
ଶ݌ܱଶ െ ݍ ൅ ݏ, (3-15)
where ݌ܱଶ  is the local oxygen partial pressure, ܦ is the diffusion coefficient for oxygen 
in the retina, ݍ is the oxygen consumption term, and ݏ is the oxygen delivery term. 
According to the Michaelis–Menten kinetics, the oxygen consumption term ݍ is 
given by, 
 ݍ ൌ ݌ܱଶ ∙ ݍ௠௔௫݌ܱଶ ൅ ܭ , (3-16)
where ݍ௠௔௫ is the maximal rate of oxygen turnover, and ܭ is a constant. 
The maximal average consumption in the outer retina during light was set to 
18mmHg/s and in darkness to 34mmHg/s.  By converting units by setting ߙଶ , the 
solubility of oxygen in retina, equal to 2.4×10−5 mL ܱଶ/(mL tissue·mmHg) [110], these 
values correspond to 2.6 and 4.9mL ܱଶ/(100g tissue·min), respectively [113].  As region 
2 occupies 20% of the outer retina and 100% of the consumption takes place there, ݍ௠௔௫ 
in this region will be 90mmHg/s in light and 170mmHg/s in darkness.  For the inner 
retina the value was set to 26mmHg/s in both light and darkness which is a value within 
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the range reported by others [113].  The delivery term ݏ describes the amount of oxygen 
transported locally from the blood to the tissue, and only applies to the inner retina since 
the outer retina does not have any blood circulation.  According to the Fick’s principle, ݏ 
is given by, 
 
ݏ ൌ ܾ݂ ቊ൫݌ܱଶ௕௟௢௢ௗ െ ߚ݌ܱଶ൯
൅ ቈ ሺ݌ܱଶ
௕௟௢௢ௗሻ௡
ሺ݌ ଶܱ௕௟௢௢ௗሻ௡ ൅ ሺܭ௛௘௠ሻ௡ െ
ሺߚ݌ܱଶሻ௡
ሺߚ݌ܱଶሻ௡ ൅ ሺܭ௛௘௠ሻ௡቉
ܪܾ ∙ ߜ
ߙଵ ቋ,
(3-17)
where ߚ is a constant, ݌ܱଶ is the local partial pressure of oxygen in the tissue, ݌ܱଶ௕௟௢௢ௗ is 
the oxygen partial pressure in blood, ܪܾ is the hemoglobin concentration in blood, ߙଵ is 
the solubility of oxygen in blood and ߜ is a constant.  The description of the hemoglobin 
saturation curve is the well-known Hill equation, and ݊  is called the Hill coefficient 
(coefficient of cooperativity).  The equation is based on the assumption that the ݌ܱଶ in 
the local venous blood can be approximated from the local average value of ݌ܱଶ in the 
retina.  The blood flow rate in the inner retina (ܾ݂) was set to 0.4mL/(g·min), for about 
normal blood flow [114].  To perform calculations for various degrees of retinal ischemia, 
ܾ݂ was decreased from the normal value 0.4mL/(g·min) such that the degree of retinal 
ischemia increased. 
The ݌ܱଶ at the chorioretinal interface was set equal to that in peripheral arterial 
blood, which is 80mmHg for normoxia.  The ݌ܱଶ and oxygen molar fluxes were set to be 
continuous at the boundaries between the regions within the retina, and the vitreoretinal 
interface. 
The list of parameters and their selected values are summarized in Table 3-3. 
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Table 3-3: The list of parameters and their selected values used in the four-layer model 
for the retina [91]. 
Parameter Value Description 
ߙଵ 1.5×10-3 mmol/(L·mmHg) The solubility of oxygen in blood 
ߙଶ 2.4×10
-5 mL ܱଶ/(mL 
tissue·mmHg) The solubility of oxygen in the retina 
ߚ 1 The ratio of the partial pressures of oxygen in venous blood and the retina 
ܾ݂ 0.4mL/(g·min) Local blood flow in the normal inner retina 
ܦ 2×10-5 cm2/s The diffusion coefficient of oxygen in the retina
ߜ 0.0616mmol/g The oxygen carrying capacity of hemoglobin 
ܪܾ 140g/L The hemoglobin concentration in blood 
ܭ௛௘௠ 26mmHg The partial pressure of oxygen at which hemoglobin is 50% saturated with oxygen 
ܭ 2mmHg The partial pressure of oxygen, at which the consumption runs at half maximal speed 
݊ 2.7 Hill coefficient 
݌ܱଶ௕௟௢௢ௗ 80mmHg Partial pressure of oxygen in arterial blood 
ݍ௠௔௫ 
26mmHg/s for region 4; 
90mmHg/s in light and 
170mmHg/s in darkness 
for region 2  
The maximal consumption rate of oxygen 
	
3.4.5 Simulation	Results	
The three-dimensional oxygen transport equations were solved numerically using 
a finite element method (COMSOL).  The meshes were made sufficiently dense such that 
further refinement did not significantly affect the solutions. 
As far as possible, the values of the input parameters were selected from the 
literature and chosen based on experimentally derived human data [88].  When human 
data were not available, values were taken from representative animal models [113]. 
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The simulation results focused on the minimal ݌ܱଶ and the oxygen consumption 
rate (i.e., oxidative metabolic rate) in the macula, an oval-shaped area of about 5mm in 
diameter at the center of the retina, which is responsible for central, high acuity vision.  
Both ݌ܱଶ  and oxygen molar fluxes across the boundaries between the regions in the 
retina and the vitreoretinal interface were set to be continuous.  The boundary condition 
at the diffuser-vitreous interface was set equal to the permeation flux of oxygen through 
the silicone wall with a thickness of 360µm. 
3.4.5.1 The Oxygenation in the Normal and Ischemic Human Eyes 
The simulation results of oxygen tension distribution in the human eye are shown 
in Figure 3-17.  The ݌ܱଶ distribution in the equatorial plane of the healthy human eye is 
shown in Figure 3-17 (a), in which the line AC is the middle line in the equatorial plane 
of the whole eye, and the line AB is the middle line in the equatorial plane of the 
macula region.  The point A is at the choroid-macular interface.  The point B is at the 
vitreomacular interface.  The point C is at the interface between the vitreous and the 
posterior lens.  The ݌ܱଶ profiles along the line A-B and the line A-C for various degrees 
of retinal ischemia are shown in Figure 3-17 (b) and (c), respectively. 
Based on the simulation results, the effects of retinal blood flow rate ܾ݂ on the 
degree of retinal ischemia, the oxygen supply rate from the retinal blood flow in the inner 
macula, the oxygen consumption rates in the inner and outer macula, and the oxygen loss 
percentage are summarized in Table 3-4.  The degree of retinal ischemia and the oxygen 
loss percentage are defined as the relative changes of blood flow rate and oxygen 
consumption rate in the inner macula as ܾ݂  decreases from the normal value 
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0.4mL/(g·min), respectively.  Here, the degree of retinal ischemia literally means the 
degree of the impairment of retinal blood flow. 
 
(a) 
 
(b) 
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(c) 
 
Figure 3-17: The simulation results of oxygen tension distribution in the human eye.  (a) 
The ݌ܱଶ distribution in the equatorial plane of the healthy human eye.  The magnified 
figure shows the detailed ݌ܱଶ distribution in the 5mm-wide macular region.  The line 
AC is the middle line in the equatorial plane of the eye, and the line AB is the middle 
line in the equatorial plane of the macula.  The point A is at the choroid-macular interface.  
The point B is at the vitreomacular interface.  The point C is at the interface between the 
vitreous and the posterior lens.  (b) The ݌ܱଶ  profile along the line A-B for various 
degrees of retinal ischemia.  (c) The ݌ܱଶ profile along the line A-C for various degrees of 
retinal ischemia. 
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Table 3-4: The effects of retinal blood flow rate ܾ݂ on the degree of retinal ischemia, the 
oxygen supply rate from the retinal blood flow in the inner macula, the oxygen 
consumption rates in the inner and outer macula, and the oxygen loss percentage. 
The retinal 
blood flow 
rate	࢈ࢌ 
(mL/g/min) 
Degree of 
retinal 
ischemia 
Oxygen supply rate 
from retinal blood 
flow in the inner 
macula (nL/min) 
Oxygen consumption 
rate (nL/min) Oxygen loss 
percentage Outer 
macula
Inner 
macula
0.400 0 84.468 63.272 86.345 0 
0.298 25.50% 79.595 63.022 83.753 3% 
0.225 43.75% 70.925 62.711 77.658 10% 
0.184 54.00% 60.767 62.489 69.161 20% 
0.153 61.75% 51.163 62.343 60.558 30% 
0.124 69.00% 41.662 62.233 51.774 40% 
0.097 75.75% 32.656 62.150 43.292 50% 
0.070 82.50% 23.59 62.080 34.648 60% 
0.043 89.25% 14.499 62.022 25.903 70% 
0.017 95.75% 5.7339 61.974 17.417 80% 
0 100.00% 0 61.946 11.843 86% 
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3.4.5.2 The Design of the Device Diffuser: Shape, Size and Control of Permeability 
We have demonstrated that the oxygen diffusion in the vitreous is the most 
limiting transport process, so that the design of the diffuser part is the most crucial step 
for the success of the device.  In the simulation of oxygenation in human eyes with 
implanted oxygen transporter devices, we will only consider the diffuser part for the 
device because we have shown that the oxygen tension in the diffuser is almost the same 
as that in the oxygen source such as the subconjunctival site.   
Here, three critical design parameters are taken into account, which are shape, 
location, and control of oxygen permeability of the diffuser.  The goal is to maximize the 
efficiency of oxygen delivery to the macula (the circular area of 5mm in diameter at the 
center of the retina), which is defined as the percentage of the total oxygen molar flow 
rate out of the diffuser that goes into the inner macula.  The ring-shaped diffuser 
surrounding the macula is much better than the disk-shaped diffuser in terms of the 
supply rate of oxygen that goes into the macula, such that in the following discussion, we 
only consider ring-shaped diffusers.  The location of diffuser is such that the ring of 
diffuser surrounds the macula.  The radius of the ring is 1mm larger than that of the 
macular region.   
Three different cross-sectional sizes of diffusers were chosen, which are 1mm in 
diameter (indicated as 1mm O-ring), 1mm by 2.5mm (indicated as 2.5mm ring), and 
1mm by 4mm (indicated as 4mm ring).  Figure 3-18 shows oxygen profiles in human 
eyes with diffusers filled up with 1atm of oxygen to treat 40% oxygen loss for ring-
shaped diffusers of the three different sizes. 
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The oxygen permeability of diffusers also needs to be controlled to prevent the 
unwanted loss of oxygen to the regions of the eye besides the macula, so we compared 
the oxygen delivery efficiencies of ring-shaped diffusers of the three sizes, for each of 
which we chose three different percentages of surfaces to be coated with impermeable 
materials such as parylene.  If parylene is not thick enough, there is still chance for 
oxygen to permeate through it.  We will utilize this property of parylene to further 
optimize the diffuser design.  The simulation results in this section will show that the 
optimal design is that almost all portions of the diffuser should be coated with thick 
parylene film due to its impermeability except the corner of the diffuser that is closest to 
the macula so as to achieve the highest oxygen delivery efficiency.  The next section will 
show that even for the corner that is nearest to the macula, we still need to coat parylene 
of some thickness to prevent too fast permeation of oxygen through pure silicone but not 
too thick to completely block the oxygen, such that pure oxygen injected into the device 
will last longer to reduce the frequency of necessary needle injection. 
Figure 3-19, Figure 3-20, and Figure 3-21 show the oxygen profiles in human 
eyes with diffusers filled up with 1atm of oxygen to treat 40% oxygen loss using ring-
shaped diffusers of the three sizes shown in Figure 3-18, respectively, for each of which 
we chose three different percentages of surfaces to be sealed by parylene. 
Table 3-5, Table 3-7, and Table 3-9 show the oxygen delivery efficiencies of ring-
shaped diffusers of the three sizes shown in Figure 3-18, respectively, for each of which 
we chose three different percentages of surfaces to be sealed by parylene. 
Table 3-6, Table 3-8, and Table 3-10 show the volume flow rates of oxygen from 
diffusers that goes into the macula for ring-shaped diffusers of the three sizes shown in 
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Figure 3-18, respectively, for each of which we chose three different percentages of 
surfaces to be sealed by parylene. 
 
 
Figure 3-18: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss using ring-shaped diffusers of three different sizes.  The 
three cross-sectional sizes of the ring-shaped diffusers are 1mm in diameter (indicated as 
1mm O-ring), 1mm by 2.5mm (indicated as 2.5mm ring), and 1mm by 4mm (indicated as 
4mm ring), respectively. 
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Figure 3-19: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss using the 1mm O-ring diffusers shown in Figure 3-18, 
for which we chose three different percentages of surfaces to be sealed by parylene.  The 
three sealing percentages are 0%, 50% and 75%, respectively. 
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Table 3-5: The oxygen delivery efficiencies of the 1mm O-ring diffusers shown in Figure 
3-18, for which we chose 0%, 50% and 75% of surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Oxygen delivery efficiency (%) 
Not sealed 50% sealed 75% sealed
40% 
0.1atm 5.578 10.119 10.587 
2atm 8.457 13.181 15.121 
30% 
0.1atm 5.66 10.203 10.732 
2atm 8.451 13.181 15.101 
20% 
0.1atm 5.667 10.182 10.747 
2atm 8.446 13.183 15.085 
10% 
0.1atm 5.521 9.921 10.394 
2atm 8.439 13.185 15.068 
 
Table 3-6: The flow rates of oxygen from diffusers that goes into the macula for the 1mm 
O-ring diffusers shown in Figure 3-18, for which we chose 0%, 50% and 75% of surfaces 
to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Volume flow rate of oxygen (nL/min)
Not sealed 50% sealed 75% sealed
40% 
0.1atm 5.281 5.068 3.944 
2atm 113.507 108.682 90.507 
30% 
0.1atm 5.194 4.985 3.884 
2atm 113.426 108.682 90.387 
20% 
0.1atm 5.010 4.804 3.741 
2atm 113.488 108.699 90.292 
10% 
0.1atm 4.628 4.439 3.428 
2atm 113.523 108.715 90.190 
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Figure 3-20: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss using the 2.5mm ring diffusers shown in Figure 3-18, 
for which we chose three different percentages of surfaces to be sealed by parylene.  The 
three sealing percentages are 0%, 50% and 88%, respectively. 
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Table 3-7: The oxygen delivery efficiencies of the 2.5mm ring diffusers shown in Figure 
3-18, for which we chose 0%, 50% and 88% of surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Oxygen delivery efficiency (%) 
Not sealed 50% sealed 88% sealed
40% 
0.1atm 5.53 13.683 11.951 
2atm 7.68 17.371 17.529 
30% 
0.1atm 5.589 13.789 12.138 
2atm 7.68 17.374 17.501 
20% 
0.1atm 5.584 13.764 12.183 
2atm 7.681 17.379 17.476 
10% 
0.1atm 5.469 13.478 11.803 
2atm 7.68 17.386 17.45 
 
Table 3-8: The flow rates of oxygen from diffusers that goes into the macula for the 
2.5mm ring diffusers shown in Figure 3-18, for which we chose 0%, 50% and 88% of 
surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Volume flow rate of oxygen (nL/min)
Not sealed 50% sealed 88% sealed
40% 
0.1atm 6.384 6.205 4.069 
2atm 127.822 124.398 94.214 
30% 
0.1atm 6.272 6.085 4.022 
2atm 127.822 124.420 94.064 
20% 
0.1atm 6.037 5.864 3.888 
2atm 129.011 124.455 93.929 
10% 
0.1atm 5.620 5.454 3.550 
2atm 128.994 124.771 93.790 
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Figure 3-21: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss using the 4mm ring diffusers shown in Figure 3-18, for 
which we chose three different percentages of surfaces to be sealed by parylene.  The 
three sealing percentages are 0%, 50% and 92%, respectively. 
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Table 3-9: The oxygen delivery efficiencies of the 4mm ring diffusers shown in Figure 
3-18, for which we chose 0%, 50% and 92% of surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Oxygen delivery efficiency (%) 
Not sealed 50% sealed 92% sealed
40% 
0.1atm 5.183 14.276 12.582 
2atm 7.04 18.204 18.659 
30% 
0.1atm 5.229 14.382 12.786 
2atm 7.042 18.207 18.632 
20% 
0.1atm 5.219 14.355 12.845 
2atm 7.044 18.211 18.607 
10% 
0.1atm 5.112 14.065 12.47 
2atm 7.045 18.218 18.578 
 
Table 3-10: The flow rates of oxygen from diffusers that goes into the macula for the 
4mm ring diffusers shown in Figure 3-18, for which we chose 0%, 50% and 92% of 
surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Volume flow rate of oxygen (nL/min)
Not sealed 50% sealed 92% sealed
40% 
0.1atm 6.569 6.496 4.265 
2atm 130.069 128.418 98.293 
30% 
0.1atm 6.443 6.368 4.197 
2atm 131.181 128.439 98.436 
20% 
0.1atm 6.208 6.137 4.060 
2atm 131.219 128.745 98.303 
10% 
0.1atm 5.784 5.713 3.713 
2atm 131.237 128.795 98.150 
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Based on the simulation data in Table 3-5, Table 3-6, Table 3-7, Table 3-8, Table 
3-9, and Table 3-10, we conclude that for each size of diffusers, it is extremely helpful to 
partially seal the surface of the diffuser to allow oxygen to only permeate out at the 
corner of the diffuser that is closest to the macula.  The size of diffusers does not matter 
too much in terms of the oxygen delivery efficiency but the smaller ring diffuser has 
smaller influence on the line of sight.  Therefore, we will choose to use 1mm O-ring 
diffuser with partial parylene coating such that oxygen only permeates out at the corner 
of the diffuser that is closest to the macula. 
However, the oxygen delivery efficiency will not be optimized if we do not 
consider the effect of the ring diameter of the ring-shaped diffuser.  In the following 
discussion, the diameter of the ring will be set to equal to that of the macula region, 5mm.   
Two different cross-sectional sizes of diffusers were chosen, which are 1mm in 
diameter (indicated as 1mm O-ring), and 1mm by 2.5mm (indicated as 2.5mm ring).  
Figure 3-22 shows the oxygen profiles in human eyes with diffusers filled up with 1atm 
of oxygen to treat 40% oxygen loss using ring-shaped diffusers of the two different sizes. 
The oxygen permeability of diffusers also needs to be controlled to prevent the 
unwanted loss of oxygen to the regions of the eye besides the macula, so we compared 
the oxygen delivery efficiencies of ring-shaped diffusers of the two sizes, for each of 
which we chose three different percentages of surfaces to be coated with impermeable 
materials such as parylene.   
Figure 3-23 and Figure 3-24 show the oxygen profiles in human eyes with 
diffusers filled up with 1atm of oxygen to treat 40% oxygen loss using ring-shaped 
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diffusers of the two sizes shown in Figure 3-22, respectively, for each of which we chose 
three different percentages of surfaces to be sealed by parylene. 
Table 3-11 and Table 3-13 show the oxygen delivery efficiencies of ring-shaped 
diffusers of the two sizes shown in Figure 3-22, respectively, for each of which we chose 
three different percentages of surfaces to be sealed by parylene. 
Table 3-12 and Table 3-14 show the volume flow rates of oxygen from diffusers 
that goes into the macula for ring-shaped diffusers of the two sizes shown in Figure 3-22, 
respectively, for each of which we chose three different percentages of surfaces to be 
sealed by parylene. 
 
 
Figure 3-22: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss usng ring-shaped diffusers of two different sizes.  The 
two cross-sectional sizes of ring-shaped diffusers are 1mm in diameter (indicated as 1mm 
O-ring), and 1mm by 2.5mm (indicated as 2.5mm ring). 
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Figure 3-23: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss using the 1mm O-ring diffusers shown in Figure 3-22, 
for which we chose three different percentages of surfaces to be sealed by parylene.  The 
three sealing percentages are 0%, 50% and 75%, respectively. 
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Table 3-11: The oxygen delivery efficiencies of the 1mm O-ring diffusers shown in 
Figure 3-22, for which we chose 0%, 50% and 75% of surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Oxygen delivery efficiency (%) 
Not sealed 50% sealed 75% sealed
40% 
100torr 23.955 43.537 53.621 
1atm 22.747 37.49 48.159 
30% 
100torr 23.763 42.429 52.634 
1atm 22.832 37.706 48.277 
20% 
100torr 23.647 42.086 52.315 
1atm 22.861 37.78 48.334 
10% 
100torr 23.539 41.839 52.063 
1atm 22.894 37.868 48.41 
 
Table 3-12: The flow rates of oxygen from diffusers that goes into the macula for the 
1mm O-ring diffusers shown in Figure 3-22, for which we chose 0%, 50% and 75% of 
surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Volume flow rate of oxygen (nL/min)
Not sealed 50% sealed 75% sealed
40% 
100torr 21.735 20.453 19.093 
1atm 117.388 112.262 105.494 
30% 
100torr 20.021 18.827 17.561 
1atm 117.704 112.466 105.417 
20% 
100torr 19.417 18.249 17.015 
1atm 117.814 112.555 105.464 
10% 
100torr 18.761 17.622 16.418 
1atm 117.934 112.660 105.537 
144 
 
 
 
 
 
Figure 3-24: The oxygen profiles in human eyes with diffusers filled up with 1atm of 
oxygen to treat 40% oxygen loss using the 2.5mm ring diffusers shown in Figure 3-22, 
for which we chose three different percentages of surfaces to be sealed by parylene.  The 
three sealing percentages are 0%, 50% and 88%, respectively. 
 
 
145 
 
Table 3-13: The oxygen delivery efficiencies of the 2.5mm ring diffusers shown in Figure 
3-22, for which we chose 0%, 50% and 88% of surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Oxygen delivery efficiency (%) 
Not sealed 50% sealed 88% sealed
40% 
100torr 20.879 52.938 59.142 
1atm 19.07 47.037 54.481 
30% 
100torr 20.592 51.928 58.363 
1atm 19.192 47.263 54.614 
20% 
100torr 20.467 51.612 58.115 
1atm 19.226 47.33 54.665 
10% 
100torr 20.364 51.38 57.927 
1atm 19.264 47.413 54.729 
 
Table 3-14: The flow rates of oxygen from diffusers that goes into the macula for the 
2.5mm ring diffusers shown in Figure 3-22, for which we chose 0%, 50% and 88% of 
surfaces to be sealed by parylene. 
Oxygen loss 
percentage 
࢖ࡻ૛ in the 
diffuser 
Volume flow rate of oxygen (nL/min)
Not sealed 50% sealed 88% sealed
40% 
100torr 22.528 21.315 19.287 
1atm 121.049 116.322 106.980 
30% 
100torr 20.753 19.620 17.759 
1atm 121.562 116.742 106.954 
20% 
100torr 20.130 19.020 17.214 
1atm 121.694 116.859 107.003 
10% 
100torr 19.454 18.370 16.616 
1atm 121.835 116.988 107.072 
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Based on the simulation data, we conclude that a diffuser with a ring diameter of 
5mm and coated with parylene partially to allow oxygen to only permeate out at the 
corner of the diffuser that is closest to the macula can achieve an estimated oxygen 
delivery efficiency of 50%, much higher than 15% for a diffuser with a ring diameter of 
7mm.  In addition, the size of diffusers does not matter too much in terms of the oxygen 
delivery efficiency, so we would rather choose the 1mm O-ring diffuser because it has 
the minimal influence on the line of sight.  The optimal design and placement of the 
diffuser for the MEMS oxygen transporter device are shown in Figure 3-25.   
 
 
Figure 3-25: The optimal design of the diffuser for the MEMS oxygen transporter device.  
The ring diameter of the diffuser is 5mm, surrounding the 5mm-wide macula region.  The 
diffuser is partially sealed with parylene such that oxygen can only permeate out at the 
corner of the diffuser that is closest to the macula.  This optimal design can achieve an 
estimated oxygen delivery efficiency of 50%.   
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3.4.5.3 The Atmospheric Oxygen as a Source to Treat Ischemic Retina 
As mentioned in the beginning, we explored two types of devices, differing in the 
oxygen sources that the devices utilize.  The oxygen source for the first type is the sub-
conjunctival site, where the ݌ܱଶ is about 100 mmHg. 
The critical ݌ܱଶ in the retinal tissue below which neovascularization is induced 
has not been identified [115].  However, the tissue ݌ܱଶ threshold value below which cells 
will die from anoxia is in the range 1–10 mmHg, depending on the cell type and other 
factors [116].  For example, in the case of the resting rat spinotrapezius muscle, the 
anoxic ݌ܱଶ  threshold is 3mmHg, whereas for cat cerebral cortex it is 7mmHg [116].  
Therefore, we chose some representative critical ݌ܱଶ values that fell into the range of 1-
10 mmHg, and each corresponding critical ܾ݂ value was such that each critical ݌ܱଶ is the 
minimal ݌ܱଶ in the inner macula resulting from that ܾ݂.  The critical ݌ܱଶ values were 
chosen to be 7.75, 4.12, and 1.61mmHg, the corresponding critical ܾ݂ values were 0.225, 
0.184, and 0.124mL/g/min, respectively, and the corresponding critical oxygen loss 
percentages in the inner macula were 10%, 20%, and 40%, respectively (Table 3-15). 
For each critical ݌ܱଶ, we simulated the ݌ܱଶ distribution in the macula after the 
device was implanted into the eye with different values of ܾ݂, and studied how well 
certain degrees of retinal ischemia could be treated.  And effects of the saccade-induced 
vitreous motion on the convective transport of oxygen were also considered by varying 
the diffusion constants of oxygen according to Table 3-2.  The simulation results of ݌ܱଶ 
distribution in the eye with ܾ݂=0.182 mL/g/min for the critical ݌ܱଶ of 7.75 mmHg and 
medium vitreous liquefaction before and after device implantation are shown in Figure 
3-26. 
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Table 3-15: The effects of the retinal blood flow rate ܾ݂ on the oxygen consumption rates 
in the inner macula, the oxygen loss percentage, and the minimal ݌ܱଶ in the inner macula. 
Retinal blood 
flow rate	࢈ࢌ 
(mL/g/min) 
Oxygen consumption 
rate in the inner 
macula (nL/min) 
Oxygen loss 
percentage 
Minimal ࢖ࡻ૛ in 
the inner macula 
(mmHg) 
0.400 86.345 0 20.30 
0.298 83.753 3% 14.43 
0.225 77.658 10% 7.75 
0.184 69.161 20% 4.12 
0.124 51.774 40% 1.61 
 
 
 
(a) 
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Figure 3-26: The simulation of oxygen tension distribution in the human eye with 
ܾ݂=0.182 mL/g/min for medium vitreous liquefaction.  (a) The three-dimensional ݌ܱଶ 
distribution in the eye with a 1mm O-ring-diffuser.  (b) The ݌ܱଶ  distribution in the 
equatorial plane of the eye with a 1mm O-ring-diffuser.  The magnified figure shows the 
detailed ݌ܱଶ distribution in the 5mm-wide macula.  The line AC is the middle line in 
the equatorial plane of the whole eye, and the line AB is the middle line in the 
equatorial plane of the macula.  The point A is at the choroid-macular interface.  The 
point B is at the vitreomacular interface.  The point C is at the interface between the 
vitreous and the posterior lens.  (c) The ݌ܱଶ profile along the line A-B before and after 
device implantation.  (d) The ݌ܱଶ  profile along the line A-C before and after device 
implantation. 
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Table 3-16: The maximal treatable oxygen loss percentage and the corresponding ܾ݂ for 
each critical ݌ܱଶ  and degree of vitreous liquefaction are listed, as well as the 
corresponding minimal ݌ܱଶ in the inner macula before and after device implantation. 
Critical ࢖ࡻ૛ 
in mmHg 
(The critical 
oxygen loss 
percentage) 
Degree of vitreous 
liquefaction 
(Equivalent diffusion 
constant of oxygen in 
the vitreous in cm2/s) 
Maximal 
treatable oxygen 
loss percentage 
(࢈ࢌ in mL/g/min)
Minimal ࢖ࡻ૛ in the 
inner macula in mmHg
Without 
device  
With 
device  
7.75 
(10%) 
Zero (4×10-5) 14.7% (0.203) 5.61 7.75 
Low (8×10-5) 17.3% (0.193) 4.77 7.75 
Medium (1.6×10-4) 20.5% (0.182) 3.99 7.75 
High (4×10-4) 23.9% (0.171) 3.33 7.75 
4.12 
(20%) 
Zero (4×10-5) 26.5% (0.163) 2.93 4.12 
Low (8×10-5) 29.9% (0.153) 2.51 4.12 
Medium (1.6×10-4) 34.0% (0.141) 2.09 4.12 
High (4×10-4) 37.9% (0.130) 1.77 4.12 
1.61 
(40%) 
Zero (4×10-5) 46.2% (0.107) 1.24 1.61 
Low (8×10-5) 48.8% (0.100) 1.12 1.61 
Medium (1.6×10-4) 52.4% (0.090) 0.95 1.61 
High (4×10-4) 56.5% (0.079) 0.78 1.61 
 
For each critical ݌ܱଶ and degree of vitreous liquefaction, the maximal treatable 
oxygen loss percentage and the corresponding retinal blood flow rate ܾ݂ which are such 
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that the minimal ݌ܱଶ in the inner macula after device implantation is brought up equal to 
the critical ݌ܱଶ, are listed in Table 3-16. 
The results show that an O-ring-shaped diffuser placed around the macula could 
provide sufficient oxygen to the ischemic macula of the human, especially at the early 
stage.  The vitreous liquefaction/vitrectomy could lead to saccade-induced convective 
transport of oxygen and increase the oxygen flux to the macula. 
 
3.4.5.4 The Injected Pure Oxygen as a Source to Treat Ischemic Retina 
The oxygen source for the second type of the device is the pure oxygen needle-
injected into the device.  In order to prevent the expansion of the device implanted into 
the eye from building up intraocular pressure (IOP) that can increase the risk of glaucoma, 
the maximal ݌ܱଶ in the device would be 1atm, under which nitrogen and all other gases 
originally in the device are flushed out by pure oxygen from needle injection.  The bag 
part of the second type of the device should have as large as volume as possible, the 
maximum of which was determined to be 13 mm by 17 mm by 3 mm because of the size 
limit underneath the conjunctiva. 
In this section, we will optimize the performance of the diffuser to minimize the 
frequency of necessary needle injection by determining the optimal oxygen permeability 
of the diffuser and back-calculating the thickness of parylene coating on silicone to 
prevent too fast or too slow oxygen permeation out of the diffuser.  The oxygen 
permeability (OP) of the diffuser wall made of the hybrid parylene/PDMS material 
ܱ ௗܲ௜௙௙௨௦௘௥	is given by,  
 
153 
 
 
1
ܱ ௗܲ௜௙௙௨௦௘௥ ൌ
1
ܱ ௉ܲ஺஼
ݐ௉஺஼
ݐ௉஺஼ ൅ ݐ௦௜௟௜௖௢௡௘ ൅
1
ܱ ௦ܲ௜௟௜௖௢௡௘
ݐ௦௜௟௜௖௢௡௘
ݐ௉஺஼ ൅ ݐ௦௜௟௜௖௢௡௘, (3-18)
where ܱ ௉ܲ஺஼  and ݐ௉஺஼  are the oxygen permeability and the thickness of parylene C, 
respectively, and ܱ ௦ܲ௜௟௜௖௢௡௘ and ݐ௦௜௟௜௖௢௡௘ are the oxygen permeability and the thickness of 
silicone, respectively.  As at the beginning of this chapter, ܱ ௦ܲ௜௟௜௖௢௡௘ , the oxygen 
permeability of the silicone MED4-4210, was measured to be 3.49104 
µL·µm/(mm2·day·atm), and ܱ ௉ܲ஺஼, the oxygen permeability of parylene C was reported 
to be 2.8µL·µm/(mm2·day·atm) [117].  In our study, ݐ௦௜௟௜௖௢௡௘  is 360 µm, and ݐ௉஺஼  is 
much smaller than ݐ௦௜௟௜௖௢௡௘, therefore eq. (3-18) can be reduced to,  
 
1
ܱ ௗܲ௜௙௙௨௦௘௥ ൌ
1
ܱ ௉ܲ஺஼
ݐ௉஺஼
ݐ௦௜௟௜௖௢௡௘ ൅
1
ܱ ௦ܲ௜௟௜௖௢௡௘, (3-19)
or, 
 
ܱ ௗܲ௜௙௙௨௦௘௥
ܱ ௦ܲ௜௟௜௖௢௡௘ ൌ
1
ܱ ௦ܲ௜௟௜௖௢௡௘ܱ ௉ܲ஺஼
ݐ௉஺஼ݐ௦௜௟௜௖௢௡௘ ൅ 1
. (3-20)
We performed the finite element simulation to determine the optimal ܱ ௗܲ௜௙௙௨௦௘௥ , for 
which the time interval between two necessary needle injections of oxygen is maximized.  
Then we could determine the thickness of parylene coating on the silicone according to 
eq. (3-19) or (3-20).  The simulation results of the oxygen permeability ratio of the 
optimal diffuser wall material to the silicone MED4-4210 and the corresponding maximal 
time of duration between two necessary needle injections of oxygen for each critical ݌ܱଶ, 
each representative initial minimal ݌ܱଶ  in the inner macula (and initial oxygen loss 
percentage), and each degree of vitreous liquefaction are summarized in Table 3-17.  
Three representative plots of the minimal ݌ܱଶ in the inner macula versus time are shown 
in Figure 3-27.   
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Table 3-17: The oxygen permeability ratio of the optimal diffuser wall material to the 
silicone MED4-4210 and the corresponding maximal time of duration between two 
necessary needle injections of oxygen for each critical ݌ܱଶ, each representative initial 
minimal ݌ܱଶ in the inner macula (and initial oxygen loss percentage), and each degree of 
vitreous liquefaction are listed. 
Critical ࢖ࡻ૛ 
in mmHg 
(The critical 
oxygen loss 
percentage) 
Initial minimal ࢖ࡻ૛ 
in the inner macular 
in mmHg 
(Initial oxygen loss 
percentage) 
Degree of vitreous 
liquefaction 
(Equivalent diffusion 
constant of oxygen in 
the vitreous in cm2/s) 
Maximal 
time of 
duration 
in days 
Optimal
ࡻࡼࢊ࢏ࢌࢌ࢛࢙ࢋ࢘
ࡻࡼ࢙࢏࢒࢏ࢉ࢕࢔ࢋ
7.75 
(10%) 
5.52 
(15%) 
Zero (4×10-5) 6.81 1/8 
Low (8×10-5) 7.77 1/12 
Medium (1.6×10-4) 8.59 1/14 
High (4×10-4) 8.44 1/14 
4.12 
(20%) 
Zero (4×10-5) 2.93 1/2 
Low (8×10-5) 3.41 1/4 
Medium (1.6×10-4) 3.76 1/5 
High (4×10-4) 3.67 1/6 
4.12 
(20%) 
3.18 
(25%) 
Zero (4×10-5) 10.92 1/14 
Low (8×10-5) 12.47 1/18 
Medium (1.6×10-4) 13.96 1/24 
High (4×10-4) 14.56 1/24 
2.51 
(30%) 
Zero (4×10-5) 4.07 1/4 
Low (8×10-5) 4.73 1/6 
Medium (1.6×10-4) 5.30 1/8 
High (4×10-4) 5.40 1/8 
1.61 
(40%) 
1.30 
(45%) 
Zero (4×10-5) 9.45 1/12 
Low (8×10-5) 10.70 1/16 
Medium (1.6×10-4) 12.13 1/20 
High (4×10-4) 13.45 1/20 
1.06 
(50%) 
Zero (4×10-5) 3.32 1/2 
Low (8×10-5) 3.87 1/4 
Medium (1.6×10-4) 4.38 1/6 
High (4×10-4) 4.66 1/7 
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(b) 
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(c) 
Figure 3-27: The minimal ݌ܱଶ in the inner macula as a function of time after the device 
filled up with 1atm of oxygen is implanted into the eye at the time equal to zero.  (a) The 
critical ݌ܱଶ  is set to be 7.75mmHg, the initial minimal ݌ܱଶ  in the inner macula is 
5.52mmHg, and the degree of vitreous liquefaction is medium.  The maximal time of 
duration between two necessary needle injections of oxygen is 8.44 days, and the 
corresponding optimal ܱ ௗܲ௜௙௙௨௦௘௥  is ܱ ௦ܲ௜௟௜௖௢௡௘ 14⁄ .  (b) The critical ݌ܱଶ  is set to be 
4.12mmHg, the initial minimal ݌ܱଶ in the inner macula is 3.18mmHg, and the degree of 
vitreous liquefaction is high.  The maximal time of duration between two necessary 
needle injections of oxygen is 14.56 days, and the corresponding optimal ܱ ௗܲ௜௙௙௨௦௘௥ is 
ܱ ௦ܲ௜௟௜௖௢௡௘ 24⁄ .  (c) The critical ݌ܱଶ is set to be 1.61mmHg, the initial minimal ݌ܱଶ in the 
inner macula is 1.30mmHg, and the degree of vitreous liquefaction is high.  The maximal 
time of duration between two necessary needle injections of oxygen is 13.45 days, and 
the corresponding optimal ܱ ௗܲ௜௙௙௨௦௘௥ is ܱ ௦ܲ௜௟௜௖௢௡௘ 20⁄ . 
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3.5 In-Vivo Animal Experiments 
We have demonstrated that the bag part of the device does not have to be too big 
because of the sufficiently large oxygen permeability of silicone, and a ring-shaped 
diffuser is the optimal design in terms of the oxygen delivery efficiency.  Therefore, in 
the in-vivo animal experiments for the implantable oxygen transporter, the bag size was 
reduced to 5mm by 3mm by 1.5mm for the first type of the device, and we chose a ring 
shape for the diffuser part.  A fabricated device is shown in Figure 3-28.  Passive MEMS 
oxygen transporter devices were implanted into rabbit eyes first to explore the long-term 
biocompatibility and stability of the devices, and there were no any adverse effects shown 
after one month. 
 
 
Figure 3-28: A photo of a fabricated device for the in-vivo animal experiments. 
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(b) 
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(c) 
Figure 3-29: The photos of a device implanted into a rabbit eye.  (a) The bag part is 
inserted underneath the conjunctiva.  (b) The cannula part penetrates the sclera at the pars 
plana.  (c) The ring-shaped diffuser is placed close to the retina and surrounds the macula. 
The photos of a device implanted into a rabbit eye are shown in Figure 3-29, in 
which the bag part is inserted underneath the conjunctiva, the cannula part containing a 
stainless steel tube penetrates the sclera at the pars plana, and the ring-shaped diffuser is 
placed very close to the retina and surrounds the macula. 
Then we performed acute in-vivo dog experiments.  To produce ischemia in dogs, 
we used laser photocoagulation to damage the blood vessels to produce retinal vein 
occlusion.  A pilot experiment was performed in dogs to obtain some preliminary data 
and to validate the experimental methods.  In three canines, pre-retinal (<0.5mm away 
from the retina) oxygen tension was recorded before and after retinal vein occlusion 
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(RVO) (Figure 3-30).  The pre-retinal oxygen tension dropped immediately from 22.13 ± 
1.14mmHg to 3.11 ± 1.45mmHg after RVO, implying the success of generating retinal 
ischemic conditions.   
In one canine, an oxygen transporter prototype was implanted.  The oxygen probe 
was positioned about 1mm away from the diffuser tip in the vitreous.  When the bag (the 
extraocular component) was exposed to the atmosphere, the oxygen tension increased 
from 12.2 ± 2.1mmHg to 92.0 ± 1.3mmHg.  When the bag was exposed to 100% oxygen 
gas, the oxygen tension recorded by the probe went above 200mmHg, beyond the probe’s 
range.  The data showed that the oxygen transporter indeed supplied oxygen to the inside 
of the eye and could bring up oxygen tension near the diffuser as expected. 
 
 
(a) 
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(b) 
Figure 3-30: (a) Laser damaging of canine retinal blood vessels to produce retinal vein 
occlusion (RVO).  The yellow circle shows the laser spot, and the red circles show the 
spots of damaged blood vessels.  (b) The pre-retinal oxygen tension before and after 
RVO.    
3.6 Summary and Conclusion 
Impaired regulation and blood flow decrease in the vascular bed that was affected 
by retinal ischemia and tissue hypoxia led to modifications of oxygen delivery and 
resulted in a damage of the neuronal cells.  The tissue hypoxia also triggers 
neovascularization. 
In this work, for the first time, a paradigm shift in the treatment of diabetic 
retinopathy is proposed: providing localized, supplemental oxygen to the ischemic tissue 
via an implantable MEMS device.  The retinal architecture (e.g., thickness, cell densities, 
layered structure, etc.) of the rabbit eye exposed to ischemic hypoxic injuries was well 
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preserved after targeted oxygen delivery to the hypoxic tissue, showing that the use of an 
external source of oxygen could improve the retinal oxygenation and prevent the 
progression of the ischemic cascade.   
The proposed MEMS device transports oxygen from an oxygen-rich space to the 
oxygen-deficient vitreous, the gel-like fluid that fills the inside of the eye, and then to the 
ischemic retina.  This oxygen transport process is purely passive and completely driven 
by the gradient of oxygen partial pressure (݌ܱଶ).  Two types of devices were designed.  
For the first type, the oxygen-rich space is underneath the conjunctiva, a membrane 
covering the sclera (white part of the eye), beneath the eyelids and highly permeable to 
oxygen in the atmosphere when the eye is open. Therefore, sub-conjunctival ݌ܱଶ is very 
high during the daytime.  For the second type, the oxygen-rich space is inside the device 
since pure oxygen is needle-injected into the device on a regular basis. 
To prevent too fast or too slow permeation of oxygen through the device that is 
made of parylene and silicone, the thicknesses of parylene and silicone became important 
design parameters that were fine-tuned to reach the optimal oxygen permeation rate.  To 
study convective transport of oxygen inside the eye induced by saccade (rapid eye 
movement), the 3D unsteady saccade-induced laminar flow of water inside the eye was 
modeled by computational fluid dynamics, and this saccade-enhanced transport effect 
was demonstrated experimentally. 
The passive MEMS oxygen transporter devices were designed, built, and tested in 
both bench-top artificial eye models and in-vitro porcine cadaver eyes.  Acute in-vivo 
animal experiments were performed in rabbits and dogs to verify the surgical procedure, 
the experimental methods and the device functionality.  Various hypotheses were 
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confirmed both experimentally and computationally.  Both our experimental and 
modeling work demonstrated the feasibility of using our MEMS oxygen transporter to 
treat retinal ischemia that occurs in diseases such as diabetic retinopathy, suggesting that 
both the two types of devices are very promising to cure diabetic retinopathy.  An O-ring-
shaped diffuser positioned as close to the macula as possible is the most efficient design 
to maintain the health of retinal cells.  For higher degree of vitreous liquefaction due to 
aging process or vitrectomy surgery, more saccade-induced convection will occur, and 
more effective the device would be to treat the retinal ischemia.  The in-vivo rabbit and 
canine eye experiments verified the surgical procedure.  Laser-photocoagulation is an 
effective means of producing retina ischemia.  The device could maintain the shape pretty 
well in the vitreous chamber of the eye, and the ݌ܱଶ measurement results showed that the 
device could transport a large amount of oxygen to the inside of the eye as expected.  The 
chronic implantation of devices in ischemic dog eyes is still underway. 
The proposed MEMS oxygen transporter devices can be also applied to treat other 
ocular and systemic diseases accompanied by retinal ischemia, such as central retinal 
artery occlusion, carotid artery disease, and some form of glaucoma.   
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CHAPTER 4 GENERAL 
CONCLUSION 
In this thesis, a passive MEMS oxygen transporter device has been developed and 
in vitro/in vivo tested.  Our device has been verified capable of delivering sufficient 
oxygen to the ischemic and hypoxic retinal tissue.  To accurately design the desired 
oxygen permeability and also improve the long-term stability of the device, the 
mechanical, thermal, barrier, and rheological properties of parylene, as well as the hybrid 
parylene/PDMS material were investigated.  Nonlinear kinetic models of parylene 
deposition into the bulk of silicone and microchannels were presented.  The results 
showed that parylene is a material highly sensitive to the deposition temperature, and 
therefore it can be tailored by choosing appropriate substrate temperatures to obtain the 
desired properties.  Another application of parylene and silicone is a capillary pressure-
driven viscometer, developed to measure the viscosity of human blood and zebrafish 
blood to demonstrate the functionality and reliability of the MEMS materials. 
Since the oxygen transporter device is made of parylene and silicone, in Chapter 2, 
the material properties of the hybrid parylene/silicone were investigated, including 
mechanical behaviors, permeation rates, and adhesive forces.  Then the thicknesses of 
parylene and silicone became important design parameters that were fine-tuned to reach 
the optimal oxygen permeation rate for the MEMS transporter device.  At higher 
deposition temperature, the as-deposited parylene C thin film exhibited higher glass 
transition temperature and β-relaxation temperature, as a result of smaller percentage of 
165 
 
amorphous phase and increasingly ordered polymer chains.  XRD scanning data indicated 
that higher deposition temperature induced greater degree of crystallinity because of 
more thermal energy available for the crystallization.  And the polymer also became 
stiffer due to less flexible polymeric chains, indicative of larger Young’s modulus.  From 
these new data, it can be concluded that parylene C’s properties could be tailored to 
specific application requirements by choosing the right deposition temperature.  In 
addition, the surface mobility of parylene monomer is a strong increasing function of 
temperature so that the gaseous monomer tends to diffuse further inside the PDMS pore 
at elevated deposition temperatures.  The enhanced pore sealing capability of parylene at 
elevated deposition temperatures can increase the adhesion between parylene and silicone.  
The PDMS pore diameter was estimated to be 6.02nm according to the nonlinear 
theoretical modeling and experimental SIMS curves.  The experimental data of the 
mechanical and barrier properties of the hybrid parylene/PDMS material agreed very well 
with the results derived from the composite material theory, suggesting that the parylene 
coatings inside PDMS pores contributed very little to the macroscopic mechanical or 
barrier properties of the hybrid parylene/PDMS material.  Deposition of parylene inside a 
microchannel holds promising applications in the surface treatment of PDMS 
microfluidic device.  Based on the preliminary experimental and theoretical results, 
parylene could penetrate into the microchannel and protect the inner surfaces better at 
elevated deposition temperatures.  Further study on the PDMS porosity is required to 
achieve more accurate and comprehensive understanding on this diffusion-reaction 
system.  At the end of Chapter 2, another application of parylene and silicone was 
presented, which is a capillary-pressure driven viscometer.  The reliability of this 
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viscometer was validated by the viscosity measurements of water and human whole 
blood.  The first experimental work on the non-Newtonian viscosity measurement of 
zebrafish whole blood was also produced using this viscometer, as an aid to understand 
the cardiac morphogenesis of congenital heart diseases.  The proposed capillary pressure-
driven viscometer required very small amount of samples, provided fast measurement, 
and produced a wide range of shear rates during a single run.  After the device calibration 
with water, the viscosity measurement of human whole blood resulted in very good 
agreement with the published data, demonstrating the reliability of the device.  The whole 
blood viscosity of zebrafish was found smaller than that of human, likely attributed to the 
smaller hematocrit for zebrafish blood. 
In Chapter 3, for the first time, a paradigm shift in the treatment of diabetic 
retinopathy is proposed: providing localized, supplemental oxygen to the ischemic tissue 
via an implantable MEMS device.  The retinal architecture (e.g., thickness, cell densities, 
layered structure, etc.) of the rabbit eye exposed to ischemic hypoxic injuries was well 
preserved after targeted oxygen delivery to the hypoxic tissue, showing that the use of an 
external source of oxygen could improve the retinal oxygenation and prevent the 
progression of the ischemic cascade.  The proposed MEMS device transports oxygen 
from an oxygen-rich space to the oxygen-deficient vitreous, the gel-like fluid that fills the 
inside of the eye, and then to the ischemic retina.  This oxygen transport process is purely 
passive and completely driven by the gradient of oxygen partial pressure (݌ܱଶ).  Two 
types of devices were designed.  For the first type, the oxygen-rich space is underneath 
the conjunctiva, a membrane covering the sclera (white part of the eye), beneath 
the eyelids and highly permeable to oxygen in the atmosphere when the eye is open.  
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Sub-conjunctival ݌ܱଶ is very high during the daytime.  For the second type, the oxygen-
rich space is inside the device since pure oxygen is needle-injected into the device on a 
regular basis.  The passive MEMS oxygen transporter devices were designed, built, and 
tested in both bench-top artificial eye models and in-vitro porcine cadaver eyes.  The 3D 
unsteady saccade-induced laminar flow of water inside the eye was modeled by 
computational fluid dynamics to study the saccade-induced convective transport of 
oxygen, and this saccade-enhanced transport effect was demonstrated experimentally.  
Acute in-vivo animal experiments were performed in dogs to verify the surgical 
procedure and the device functionality.  Various hypotheses were confirmed both 
experimentally and computationally, suggesting that both the two types of devices are 
very promising to cure diabetic retinopathy.  The chronic implantation of devices in 
ischemic dog eyes is still underway.  The proposed MEMS oxygen transporter devices 
can be also applied to treat other ocular and systemic diseases accompanied by retinal 
ischemia, such as central retinal artery occlusion, carotid artery disease, and some form of 
glaucoma. 
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